Pyridopyrimidine derivatives for use as antiviral agents

Polyyclic heterocyclic compounds targeting the viral envelope offer a new approach to treat enveloped virus infections, addressing the limited treatment options for viral infections by disrupting the viral envelope, effectively reducing infectivity and providing a therapeutic solution for enveloped viruses like coronaviruses.

WO2024235876A1PCT designated stage expired Publication Date: 2024-11-21FERNANDEZ-CAPETILLO OSCAR
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2024/062995
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-12
Filing Date
2024-05-10
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Current treatments for viral infections, particularly those caused by enveloped viruses like coronaviruses, are limited, with few effective antiviral options available for preventing infection or treating the virus, often relying on vaccination or symptom management, highlighting a need for new therapeutic approaches.

Method used

Development of specific polyyclic heterocyclic compounds that disrupt the viral envelope or its interaction with the host membrane, offering a novel mechanism to prevent or treat infections with enveloped viruses, such as coronaviruses, by targeting the viral envelope.

Benefits of technology

These compounds demonstrate antiviral effects by reducing viral infectivity and stability, providing a potential therapeutic option for enveloped virus infections, including coronaviruses, with a focus on preventing and treating infections effectively.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure EP2024062995_21112024_PF_FP_ABST
    Figure EP2024062995_21112024_PF_FP_ABST
Patent Text Reader

Abstract

There are herein provided compounds of Formula (I), wherein R1, R2, L, X, Y, Z, n, and m are as defined in the description. Medical uses of compounds of Formula (I) are also provided herein.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] POLYCYCLIC HETEROCYCLES FOR USE IN THE TREATMENT OF AN INFECTION WITH AN ENVELOPED VIRUS Field of the invention The present invention relates to novel compounds and compositions, and their use in the prevention and treatment of an infection with an enveloped virus, such as those from the family of coronaviruses. Background of the invention The listing or discussion of an apparently prior-published document in this specification should not necessarily be taken as an acknowledgement that the document is part of the state of the art or is common general knowledge. Viruses can infect all life forms, from animals and plants to micro-organisms. Viral infections affecting humans and animals are a global health concern due to their ability to spread rapidly, and their potential to cause serious health issues and even death. Viruses display a wide diversity of morphologies. For example, depending on the presence or absence of an outer phospholipid bilayer, viruses can be grouped into “enveloped” and “non-enveloped” viruses. The viral envelope is studded with proteins coded for by the viral genome and host genome; the lipid membrane itself and any carbohydrates present originate entirely from the host. Influenza virus, HIV (which causes AIDS), and severe acute respiratory syndrome coronavirus 2 (which causes COVID-19) use this strategy, and so are considered “enveloped viruses”. Most enveloped viruses are dependent on the envelope for their infectivity and the stability of the viral material outside of a host organism. Compared to the treatment of infection with other pathogens, adequate treatments for viral infections are comparatively rare. Furthermore, few example of antivirals that prevent the infection step such as fostemsavir or maraviroc are available, and most are directed to prevent other steps of the viral replication cycle. In the absence of effective treatments, public health strategies often resort to either vaccination as a means for prevention of infection, or the use of therapeutic agents to manage the symptoms of the infection. Thus, there is an urgent need for further treatment and prevention therapies for infections with an enveloped virus, such as coronavirus. Description of the Invention It has now been surprisingly found that certain compounds are effective in the prevention and treatment of infections with an enveloped virus. Without wishing to be bound by theory, it is believed that such compounds achieve this effect by disrupting the viral envelope or its interaction with the host membrane. Compounds for use In a first aspect of the invention, there is provided a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in preventing or treating an infection with an enveloped virus, wherein: L represents -C(O)-, -S(O)2- or -N(R7)C(O)-; n represents 1 to 5; m represents 1 or 2; each R1independently represents (a) C1-12 alkyl, C2-12 alkenyl or C2-12 alkynyl each optionally substituted by one or more groups independently selected from G1a, (b) -ORa1, (c) -SO2Rb1, (d) halo, (e) aryl optionally substituted by one or more groups independently selected from G1b, (f) heteroaryl optionally substituted by one or more groups independently selected from G1c, or (g) heterocyclyl optionally substituted by one or more groups independently selected from G1d; and any two adjacent R1groups together with the carbons to which they are attached may alternatively form an aryl ring, optionally substituted by one or more groups independently selected from G1b; Ra1represents C2-12alkyl optionally substituted by one or more groups independently selected from G2a; Rb1represents C1-12 alkyl optionally substituted by one or more groups independently selected from G3a; each G1a, G2a, G3a, G4a, G5a, G6a, and G7aindependently represents halo, -CN, - N(Rb2)Rc2, -ORd2, -SRe2or =O; each G1band G1cindependently represents halo, Ra2, -CN, -N(Rb2)Rc2, -ORd2, or -SRe2; each G1dindependently represents halo, Ra2, -CN, -N(Rb2)Rc2, -ORd2, -SRe2, or =O; each Ra2represents C1-6 alkyl optionally substituted by one or more groups independently selected from G4a; each Rb2, Rc2, Rd2, and Re2independently represents H or C1-6 alkyl, C2-6 alkenyl or C2- 6 alkynyl each optionally substituted by one or more fluoro; or Rb2and Rc2are linked together to form, along with the nitrogen atom to which they are attached, a 3- to 6-membered ring, which ring optionally contains one further heteroatom and which ring optionally is substituted by one or more groups independently selected from fluoro, C1-3alkyl, C2-3alkenyl or C2-3alkynyl each optionally substituted by one or more fluoro; R2represents -NR3R4or -OR5; R3represents H or C1-6 alkyl optionally substituted by one or more groups independently selected from G5a; R4represents C1-6alkyl optionally substituted by one or more groups independently selected from G6a; R5represents C1-6alkyl; one of X and Z represents NR6, and the other represents CH2; Y represents CH or N; R6represents H, C1-6alkyl optionally substituted by one or more groups independently selected from G7a; R7represents H or C1-6 alkyl; wherein each alkyl, alkenyl, and alkynyl group may be linear, branched, or where there is a sufficient number of carbons, may be cyclic or part cyclic, which compounds (including pharmaceutically acceptable salts) may be referred to herein as the “compounds of the invention” or “compounds of the first aspect of the invention”. For the avoidance of doubt, the skilled person will understand that references herein to compounds of particular aspects of the invention (such as the first aspect of the invention, e.g. compounds of formula I) will include references to all embodiments and particular features thereof, which embodiments and particular features may be taken in combination to form further embodiments. Unless indicated otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Pharmaceutically acceptable salts include acid addition salts and base addition salts. Such salts may be formed by conventional means, for example by reaction of a free acid or a free base form of a compound of the invention with one or more equivalents of an appropriate acid or base, optionally in a solvent, or in a medium in which the salt is insoluble, followed by removal of said solvent, or said medium, using standard techniques (e.g. in vacuo, by freeze-drying or by filtration). Salts may also be prepared by exchanging a counter-ion of a compound of the invention in the form of a salt with another counter-ion, for example using a suitable ion exchange resin. Particular acid addition salts that may be mentioned include carboxylate salts (e.g. formate, acetate, trifluoroacetate, propionate, isobutyrate, heptanoate, decanoate, caprate, caprylate, stearate, acrylate, caproate, propiolate, ascorbate, citrate, glucuURQDWH^^JOXWDPDWH^^JO\FRODWH^^Į-hydroxybutyrate, lactate, tartrate, phenylacetate, mandelate, phenylpropionate, phenylbutyrate, benzoate, chlorobenzoate, methylbenzoate, hydroxybenzoate, methoxybenzoate, dinitrobenzoate, o-acetoxy- benzoate, salicylate, nicotinate, isonicotinate, cinnamate, oxalate, malonate, succinate, suberate, sebacate, fumarate, malate, maleate, hydroxymaleate, hippurate, phthalate or terephthalate salts), halide salts (e.g. chloride, bromide or iodide salts), sulphonate salts (e.g. benzenesulphonate, methyl-, bromo- or chloro- benzenesulphonate, xylenesulphonate, methanesulphonate, ethanesulphonate, propanesulphonate, hydroxy-ethanesulphonate, 1- or 2- naphthalene-sulphonate or 1,5-naphthalenedisulphonate salts) or sulphate, pyrosulphate, bisulphate, sulphite, bisulphite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate or nitrate salts, and the like. Particular acid addition salts that may be mentioned include the hydrochloride salt. For the avoidance of doubt, the skilled person will understand that acid addition salts may include diacid salts (e.g. dihydrochloride salts). For the avoidance of doubt, compounds of the first aspect of the invention may exist as solids, and thus the scope of the invention includes all amorphous, crystalline and part crystalline forms thereof, and may also exist as oils. Where compounds of the first aspect of the invention exist in crystalline and part crystalline forms, such forms may include solvates, which are included in the scope of the invention. Compounds of the first aspect of the invention may also exist in solution. Compounds of the first aspect of the invention may contain double bonds and may thus exist as E (entgegen) and Z (zusammen) geometric isomers about each individual double bond. All such isomers and mixtures thereof are included within the scope of the invention. As used herein, references to halo and / or halogen groups will each independently refer to fluoro, chloro, bromo and iodo (for example, fluoro (F) and chloro (Cl), such as F). Unless otherwise specified, C1-zalkyl groups (where z is the upper limit of the range) defined herein may be straight-chain or, when there is a sufficient number (i.e. a minimum of three) of carbon atoms, be branched-chain and / or cyclic (so forming a C3-z-cycloalkyl group). When there is a sufficient number (i.e. a minimum of four) of carbon atoms, such groups may also be part cyclic. Part cyclic alkyl groups that may be mentioned include cyclopropylmethyl and cyclohexylethyl. When there is a sufficient number of carbon atoms, such groups may also be multicyclic (e.g. bicyclic or tricyclic) or spirocyclic. For the avoidance of doubt, alkyl groups may be linear (otherwise referred to as straight-chained), branched (otherwise referred to as branched-chain) and / or cyclic. More particularly, alkyl groups may be linear (otherwise referred to as straight- chained) or branched (otherwise referred to as branched-chain). Unless otherwise specified, C2-zalkenyl groups (where z is the upper limit of the range) defined herein may be straight-chain or, when there is a sufficient number (i.e. a minimum of three) of carbon atoms, be branched-chain, and / or be cyclic. Unless otherwise specified, C2-zalkynyl groups (where z is the upper limit of the range) defined herein may be straight-chain or, when there is a sufficient number (i.e. a minimum of four) of carbon atoms, be branched-chain, and / or when there is a sufficient number (i.e. a minimum of eight) of carbon atoms, be cyclic. For the avoidance of doubt, the skilled person will understand that the term alkyl will refer to saturated hydrocarbon moieties, whereas the term alkenyl will refer to unsaturated hydrocarbon moieties containing at least one carbon-carbon double bond and the term alkynyl will refer to unsaturated hydrocarbon moieties containing at least one carbon-carbon triple bond. For the avoidance of doubt, as used herein, references to heteroatoms will take their normal meaning as understood by one skilled in the art. Particular heteroatoms that may be mentioned include phosphorus, selenium, tellurium, silicon, boron, oxygen, nitrogen and sulphur (e.g. oxygen, nitrogen and sulphur). As used herein, the term heterocyclyl may refer to non-aromatic monocyclic and bicyclic heterocyclyl groups (which groups may further be bridged) in which at least one (e.g. one to four) of the atoms in the ring system is other than carbon (i.e. a heteroatom), and in which the total number of atoms in the ring system is between three and twelve (e.g. between five and ten and, most preferably, between three and eight, e.g. a 5- or 6-membered heterocyclyl group). Further, such heterocyclyl groups may be saturated, forming a heterocycloalkyl, or unsaturated containing one or more carbon-carbon or, where possible, carbon-heteroatom or heteroatom-heteroatom double and / or triple bonds, forming for example a C2-z(e.g. C4-z) heterocycloalkenyl (where z is the upper limit of the range) or a C7-z heterocycloalkynyl group. C2-z heterocyclyl groups that may be mentioned include 7-azabicyclo-[2.2.1]heptanyl, 6- azabicyclo[3.1.1]heptanyl, 6-azabicyclo[3.2.1]-octanyl, 8-azabicyclo[3.2.1]octanyl, aziridinyl, azetidinyl, 2,3-dihydroisothiazolyl, dihydropyranyl, dihydropyridinyl, dihydropyrrolyl (including 2,5-dihydropyrrolyl), dioxolanyl (including 1,3-dioxolanyl), dioxanyl (including 1,3-dioxanyl and 1,4-dioxanyl), dithianyl (including 1,4-dithianyl), dithiolanyl (including 1,3-dithiolanyl), imidazolidinyl, imidazolinyl, isothiazolidinyl, morpholinyl, 7-oxabicyclo[2.2.1]heptanyl, 6-oxabicyclo[3.2.1]-octanyl, oxetanyl, oxiranyl, piperazinyl, piperidinyl, pyranyl, pyrazolidinyl, pyrrolidinonyl, pyrrolidinyl, pyrrolinyl, quinuclidinyl, sulfolanyl, 3-sulfolenyl, tetrahydropyranyl, tetrahydrofuryl, tetrahydropyridinyl (such as 1,2,3,4-tetrahydropyridinyl and 1,2,3,6- tetrahydropyridinyl), thietanyl, thiiranyl, thiolanyl, tetrahydrothiopyranyl, thiomorpholinyl, trithianyl (including 1,3,5-trithianyl), tropanyl and the like. Substituents on heterocyclyl groups may, where appropriate, be located on any atom in the ring system including a heteroatom. Further, in the case where the substituent is another cyclic compound, then the cyclic compound may be attached through a single atom on the heterocyclyl group, forming a so-called “spiro”-compound. The point of attachment of heterocyclyl groups may be via any atom in the ring system including (where appropriate) a further heteroatom (such as a nitrogen atom), or an atom on any fused carbocyclic ring that may be present as part of the ring system. Heterocyclyl groups may also be in the N- or S- oxidised form. At each occurrence when mentioned herein, particular heterocyclyl groups that may be mentioned include 3- to 8-membered heterocyclyl groups (e.g. a 4- to 6-membered heterocyclyl group). As may be used herein, the term aryl includes references to C6 -14(e.g. C6 -10) aromatic groups. Such groups may be monocyclic or bicyclic and, when bicyclic, be either wholly or partly aromatic. C6-10 aryl groups that may be mentioned include phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, indanyl, and the like (e.g. phenyl, naphthyl and the like, such as phenyl). For the avoidance of doubt, the point of attachment of substituents on aryl groups may be via any carbon atom of the ring system. As may be used herein, the term heteroaryl (or heteroaromatic) includes references to 5- to 14- (e.g. 5- to 10-) membered heteroaromatic groups containing one or more heteroatoms selected from oxygen, nitrogen and / or sulfur. Such heteroaryl groups may comprise one, two, or three rings, of which at least one is aromatic. Substituents on heteroaryl / heteroaromatic groups may, where appropriate, be located on any atom in the ring system including a heteroatom. The point of attachment of heteroaryl / heteroaromatic groups may be via any atom in the ring system including (where appropriate) a heteroatom. Bicyclic heteroaryl / heteroaromatic groups may comprise a benzene ring fused to one or more further aromatic or non-aromatic heterocyclic rings, in which instances, the point of attachment of the polycyclic heteroaryl / heteroaromatic group may be via any ring including the benzene ring or the heteroaryl / heteroaromatic or heterocyclyl ring. Examples of heteroaryl / heteroaromatic groups that may be mentioned include pyridinyl, pyrrolyl, furanyl, thiophenyl, oxadiazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazolyl, triazolyl, tetrazolyl, isoxazolyl, isothiazolyl, imidazolyl, imidazopyrimidinyl, imidazothiazolyl, thienothiophenyl, pyrimidinyl, furopyridinyl, indolyl, azaindolyl, pyrazinyl, pyrazolopyrimidinyl, indazolyl, pyrimidinyl, quinolinyl, isoquinolinyl, quinazolinyl, benzofuranyl, benzothiophenyl, benzoimidazolyl, benzoxazolyl, benzothiazolyl, benzotriazolyl and purinyl. The oxides of heteroaryl / heteroaromatic groups are also embraced within the scope of the invention (e.g. the N-oxide). As stated above, heteroaryl includes polycyclic (e.g. bicyclic) groups in which one ring is aromatic (and the other may or may not be aromatic). Hence, other heteroaryl groups that may be mentioned include e.g. benzo[1,3]dioxolyl, benzo[1,4]dioxinyl, dihydrobenzo[d]isothiazole, 3,4-dihydrobenz[1,4]oxazinyl, dihydrobenzothiophenyl, indolinyl, 5H,6H,7H-pyrrolo[1,2-b]pyrimidinyl, 1,2,3,4-tetrahydroquinolinyl, thiochromanyl and the like. For the avoidance of doubt, references to polycyclic (e.g. bicyclic or tricyclic) groups (e.g. when employed in the context of cycloalkyl groups) will refer to ring systems wherein at least two scissions would be required to convert such rings into a straight chain, with the minimum number of such scissions corresponding to the number of rings defined (e.g. the term bicyclic may indicate that a minimum of two scissions would be required to convert the rings into a straight chain). For the avoidance of doubt, the term bicyclic (e.g. when employed in the context of alkyl groups) may refer to groups in which the second ring of a two-ring system is formed between two adjacent atoms of the first ring, and may also refer to groups in which two non-adjacent atoms are linked by an alkylene group, which later groups may be referred to as bridged. For the avoidance of doubt, when an aryl or an heteroaryl group is substituted with a group via a double bond, such as =O, it is understood that the aryl or heteroaryl group is partly aromatic, i.e. the aryl or heteroaryl group consists of at least two rings where at least one ring is not aromatic. The present invention also embraces isotopically-labelled compounds of the present invention which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature (or the most abundant one found in nature). All isotopes of any particular atom or element as specified herein are contemplated within the scope of the compounds of the invention. Hence, the compounds of the invention also include deuterated compounds, i.e. in which one or more hydrogen atoms are replaced by the hydrogen isotope deuterium. For the avoidance of doubt, in cases in which the identity of two or more substituents in a compound of the invention may be the same, the actual identities of the respective substituents are not in any way interdependent. For example, in the situation in which two or more R1groups are present, those R1groups may be the same or different. Similarly, where two or more R1groups are present and each represent halo, the halo groups in question may be the same or different. Likewise, when more than one R1is present and each independently represents C1-6alkyl substituted by one or more G1a, the identities of each G1aare in no way interdependent. The skilled person will appreciate that compounds of the invention that are the subject of this invention include those that are stable. That is, compounds of the invention include those that are sufficiently robust to survive isolation, e.g. from a reaction mixture, to a useful degree of purity. All embodiments of the invention and particular features mentioned herein may be taken in isolation or in combination with any other embodiments and / or particular features mentioned herein (hence describing more particular embodiments and particular features as disclosed herein) without departing from the disclosure of the invention. In particular embodiments, n represents 1 to 4 (such as 1 to 3, or 1 to 2). In particular embodiments, n represents 1. In particular embodiments, each R1independently represents (a) C1-12alkyl (such as C2-12alkyl), C2-12alkenyl or C2-12alkynyl each optionally substituted by one or more groups independently selected from G1a, (b) -ORa1, (c) -SO2Rb1, (d) halo, (e) aryl optionally substituted by one or more groups independently selected from G1b, or (f) heterocyclyl optionally substituted by one or more groups independently selected from G1d; and any two adjacent R1groups together with the carbons to which they are attached may alternatively form an aryl ring, optionally substituted by one or more groups independently selected from G1b. In more particular embodiments, each R1independently represents (a) C1-12alkyl (such as C2-12alkyl), C2-12alkenyl or C2-12alkynyl each optionally substituted by one or more groups independently selected from G1a, (b) -ORa1, (c) -SO2Rb1, (d) aryl optionally substituted by one or more groups independently selected from G1b, or (e) heterocyclyl optionally substituted by one or more groups independently selected from G1d; and any two adjacent R1groups together with the carbons to which they are attached may alternatively form an aryl ring, optionally substituted by one or more groups independently selected from G1b. In more particular embodiments, each R1independently represents (a) C1-12alkyl (such as C2-12alkyl), each optionally substituted by one or more groups independently selected from G1a, (b) -ORa1, (c) -SO2Rb1, (d) aryl optionally substituted by one or more groups independently selected from G1b, or (e) heterocyclyl optionally substituted by one or more groups independently selected from G1d; and any two adjacent R1groups together with the carbons to which they are attached may alternatively form an aryl ring, optionally substituted by one or more groups independently selected from G1b. In more particular embodiments, each R1independently represents (a) C1-12alkyl (such as C2-12alkyl), each optionally substituted by one or more groups independently selected from G1a, (b) -ORa1, (c) aryl optionally substituted by one or more groups independently selected from G1b, or (d) heterocyclyl optionally substituted by one or more groups independently selected from G1d; and any two adjacent R1groups together with the carbons to which they are attached may alternatively form an aryl ring, optionally substituted by one or more groups independently selected from G1b. In particular embodiments, at least one (or, when only one such group is present, the) R1group represents C2-12 alkyl, such as C4-12 alkyl or C4-8 alkyl. In particular embodiments, at least one (or, when only one such group is present, the) R1group represents -ORa1. In particular such embodiments, Ra1represents C2-12 alkyl, such as C4-12 alkyl or C4-8 alkyl. In more particular embodiments, Ra1represents C4-6 alkyl, such as butyl. In particular embodiments, at least one (or, when only one such group is present, the) R1group represents phenyl, optionally substituted by one or more groups independently selected from G1b. In particular embodiments, at least one (or, when only one such group is present, the) R1group represents heterocyclyl. In particular such embodiments, the heterocyclyl is a 5- or 6-membered heterocycloalkyl comprising one to three heteroatoms selected from N, O, and S, such as selected from N and O. In more particular embodiments, the heterocycloalkyl comprises one to three N atoms. In more particular such embodiments, the heterocyclyl contains only one heteroatom, and the heteroatom is the point of attachment of R1to the remainder of the molecule. In particular such embodiments, the heterocyclyl is heterocycloalkyl. In particular embodiments, any two adjacent R1groups together with the carbons to which they are attached may alternatively form an aryl ring, optionally substituted by one or more groups independently selected from G1b. In more particular embodiments, any two adjacent R1groups together with the carbons to which they are attached may alternatively form a phenyl ring. As such, in such embodiments, the essential phenyl ring of formula (I) is part of a naphthalene group. In even more particular embodiments, an R1group attached at the 4-position of the essential phenyl ring (i.e. the para position of the essential phenyl ring of formula (I)) together with an R1group attached at the 3-position of the essential phenyl ring form a phenyl ring. In particular embodiments, at least one (or, when only one such group is present, the) R1group is attached at the 4-position of the phenyl ring (i.e. the para position of the essential phenyl ring of formula (I)). In particular embodiments, at least one (or, when only one such group is present, the) R1group is attached at the 3-position of the phenyl ring (i.e. the meta position of the essential phenyl ring of formula (I)). In particular embodiments, at least one (or, when only one such group is present, the) R1group is attached at the 2-position of the phenyl ring (i.e. the ortho position of the essential phenyl ring of formula (I)). In particular embodiments, R2represents -NR3R4. In particular embodiments, R3represents H and / or (e.g. and) R4represents C1-6 alkyl (such as C1-4 alkyl (such as methyl or ethyl)), optionally wherein R4is substituted by one or more groups independently selected from G6a. As such, in more particular embodiments, R3represents H and / or (e.g. and) R4represents methyl. In alternative embodiments, R3represents C1-6alkyl, such as C1-4alkyl (such as methyl or ethyl) optionally substituted by one or more groups independently selected from G5a; and R4represents C1-6 alkyl, such as C1-4 alkyl (such as methyl or ethyl), optionally wherein R4is substituted by one or more groups independently selected from G6a. In more particular embodiments, R3and R4represent methyl. In alternative embodiments, R2represents -OR5. In particular such embodiments, R5represents C1-4 alkyl, such as ethyl or methyl. In particular embodiments, X represents NR6. In more particular embodiments, R6represents H. In alternative embodiments, R6represents C1-6 alkyl, such as C1-4 alkyl, such as methyl. In alternative embodiments, Y represents NR6. In more particular embodiments, R6represents H. In alternative embodiments, R6represents C1-6 alkyl, such as C1-4 alkyl, such as methyl. For the avoidance of doubt, when Y represents NR6, X represents CH2. In particular embodiments, L represents -C(O)-, -S(O)2- or -N(R7)C(O)-. In particular embodiments, when L represents -N(R7)C(O)-, R7represents H. In particular embodiments, m represents 1. In particular embodiments, m represents 2. In particular embodiments, each G1a, G2a, G3a, G4a, G5a, G6a, and G7aindependently represents halo (such as chloro or fluoro), -CN, -N(Rb2)Rc2, -ORd2, or =O. In more particular embodiments, each G1a, G2a, G3a, G4a, G5a, G6a, and G7aindependently represents halo (such as chloro or fluoro), -N(Rb2)Rc2, -ORd2, or =O. In more particular embodiments, each G1a, G2a, G3a, G4a, G5a, G6a, and G7aindependently represents halo (such as chloro or fluoro), -ORd2, or =O. In more particular embodiments, each G1a, G2a, G3a, G4a, G5a, G6a, and G7aindependently represents halo (such as chloro or fluoro). For the avoidance of doubt, as indicated herein, embodiments of the invention will include combinations of embodiments as described herein. For example, in certain embodiments that may be mentioned: L represents -C(O)-, -S(O)2- or -NHC(O)-; n represents 1 to 3; R1represents (a) C1-12 alkyl (such as C2-12 alkyl), C2-12 alkenyl or C2-12 alkynyl each optionally substituted by one or more groups independently selected from G1a, (b) -ORa1, (c) -SO2Rb1, (d) halo, (e) aryl optionally substituted by one or more groups independently selected from G1b, or (f) heterocyclyl optionally substituted by one or more groups independently selected from G1d, or two R1groups, together with the carbons to which they are attached form a phenyl ring, optionally substituted by one or more groups independently selected from G1b; Ra1represents C2-12 alkyl, such as C4-12 alkyl or C4-8 alkyl; and R2represents -NR3R4. In further embodiments that may be mentioned: L represents -C(O)-, -S(O)2- or -NHC(O)- (such as -C(O)-); n represents 1 or 2; R1represents C1-6 alkyl, -OR1a, phenyl, heterocyclyl, wherein the heterocyclyl contains only one heteroatom and the heteroatom is the point of attachment of R1to the remainder of the molecule, or or two R1groups, together with the carbons to which they are attached form a phenyl ring; R1arepresents C4-12alkyl or C4-8alkyl, such as butyl; and R2represents -NR3R4. In more particular such embodiments: R3represents H or C1-4 alkyl (such as propyl, ethyl, or methyl, such as methyl); R4represents C1-4alkyl (such as propyl, ethyl, or methyl, such as methyl); and / or (e.g. and) R6represents H or C1-4 alkyl (such as propyl, ethyl, or methyl, such as methyl). Particular compounds of the invention (e.g. compounds of formula (I)) include those described in the examples herein. For example, particular compounds of the first aspect of the invention are selected from the list consisting of: [3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl]pyrrolidin-1-yl]- [4-(4-methyl-1-piperidyl)phenyl]methanone; [3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl]pyrrolidin-1-yl]- (4-pentylphenyl)methanone; (4-butylphenyl)-[3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2- yl]pyrrolidin-1-yl]methanone; [3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl]pyrrolidin-1-yl]- (4-propylphenyl)methanone; (4-ethylphenyl)-[3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2- yl]pyrrolidin-1-yl]methanone; [3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl]pyrrolidin-1-yl]- (2-naphthyl)methanone; (4-butoxyphenyl)-[3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2- yl]pyrrolidin-1-yl]methanone; [3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl]pyrrolidin-1-yl]- (4-phenylphenyl)methanone; (4-cyclohexylphenyl)-[3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin- 2-yl]pyrrolidin-1-yl]methanone; [4-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl]piperazin-1-yl]- [4-(4-methyl-1-piperidyl)phenyl]methanone; [3-[7-methyl-4-(methylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-2- yl]pyrrolidin-1-yl]-[4-(4-methyl-1-piperidyl)phenyl]methanone; [3-[7-methyl-4-(methylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-2- yl]pyrrolidin-1-yl]-[4-(4-methyl-1-piperidyl)phenyl]methanone hydrochloride; [3-[4-(dimethylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl]pyrrolidin-1- yl]-[4-(4-methyl-1-piperidyl)phenyl]methanone; N-methyl-2-[1-(4-phenylphenyl)sulfonylpyrrolidin-3-yl]-5,6,7,8- tetrahydropyrido[3,4-d]pyrimidin-4-amine; 2-[1-(4-butylphenyl)sulfonylpyrrolidin-3-yl]-N-methyl-5,6,7,8-tetrahydropyrido[3,4- d]pyrimidin-4-amine; 3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl]-N-(4- phenylphenyl)pyrrolidine-1-carboxamide; N-(4-butylphenyl)-3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2- yl]pyrrolidine-1-carboxamide; [3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-yl]pyrrolidin-1-yl]- [4-(4-methyl-1-piperidyl)phenyl]methanone; [4-(4-methoxy-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)piperazin-1-yl]-[4-(4- methyl-1-piperidyl)phenyl]methanone; and [4-[4-(dimethylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl]piperazin-1- yl]-[4-(4-methyl-1-piperidyl)phenyl]methanone, and pharmaceutically acceptable salts thereof. In particular embodiments, the enveloped virus is a coronavirus. In more particular embodiments, the coronavirus is alphacoronavirus or betacoronavirus. In more particular embodiments, the alphacoronavirus is Human coronavirus 229E (HCoV-229E) or Human coronavirus NL63 (HCoV-NL63). In alternative embodiments, the betacoronavirus is selected from the group consisting of severe acute respiratory syndrome-related coronavirus, Middle East respiratory syndrome (MERS), SARS-Cov-2, Human coronavirus OC43, Human coronavirus HKU1. In particular such embodiments, the severe acute respiratory syndrome-related coronavirus is SARS-Cov-1 or SARS-Cov-2. In particular embodiments, the enveloped virus is of Orthopoxvirus genus, such as of Poxviridae family, such as of Chordopoxviridae subfamily. In more particular embodiments, the enveloped virus of Orthopoxvirus genus is selected from monkeypox, cowpox, smallpox, camelpox, or horsepox, such as monkeypox. In particular embodiments, the enveloped virus of Poxviridae family and Chordopoxviridae subfamily is monkeypox. In particular embodiments, the enveloped virus is of Flavivirus genus, such as of Flaviviridae family. In more particular embodiments, the enveloped virus of Flavivirus genus is selected from Tick-borne Encephalitis Virus (TBEV), Zika, Dengue, West Nile, or Yellow fever, such as TBEV. In particular embodiments, the enveloped virus of Flaviviridae family is TBEV. In an alternative first aspect of the invention, there is provided the use of a compound of formula (I) as defined above in the first aspect of the invention, for the manufacture of a medicament for preventing or treating an infection with an enveloped virus. In a further alternative first aspect of the invention, there is provided a method of preventing or treating an infection with an enveloped virus, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) defined above in the first aspect of the invention. For the avoidance of doubt, references to compounds as defined in the first aspect of the invention will include references to compounds of formula I (including all embodiments thereof) and pharmaceutically acceptable salts thereof. The skilled person will understand that references to the treatment of a particular condition (or, similarly, to treating that condition) take their normal meanings in the field of medicine. In particular, the terms may refer to achieving a reduction in the severity of one or more clinical symptom associated with the condition. For example, in the case of an enveloped virus (such as a coronavirus), the term may refer to (a) achieving a reduction in symptoms in infected patients such as fever, couching, feeling tired or exhausted, aching, headache, or loss of appetite, or (b) preventing the infection and the onset of the disease when being exposed to the virus. As used herein, references to patients will refer to a living subject being treated, including mammalian (e.g. human) patients. Thus, in particular embodiments of the first aspect of the invention, the treatment is in a mammal (e.g. a human). As used herein, the term therapeutically effective amount will refer to an amount of a compound that confers a therapeutic effect on the treated patient. The effect may be objective (i.e. measurable by some test or marker) or subjective (i.e. the subject gives an indication of and / or feels an effect). Although compounds of the first aspect of the invention may possess pharmacological activity as such, certain pharmaceutically-acceptable (e.g. “protected”) derivatives of compounds of the invention may exist or be prepared which may not possess such activity, but may be administered parenterally or orally and thereafter be metabolised in the body to form compounds of the invention. Such compounds (which may possess some pharmacological activity, provided that such activity is appreciably lower than that of the active compounds to which they are metabolised) may therefore be described as “prodrugs” of compounds of the invention. As used herein, references to prodrugs will include compounds that form a compound of the invention, in an experimentally-detectable amount, within a predetermined time, following enteral or parenteral administration (e.g. oral or parenteral administration). All prodrugs of the compounds of the first aspect of the invention are included within the scope of the invention. As used herein, the term prevention (and, similarly, preventing) includes references to the prophylaxis of the disease or disorder (and vice-versa). As such, references to prevention may also be references to prophylaxis, and vice versa. In particular, the term may refer to achieving a reduction in the likelihood of the patient (or healthy subject) developing the condition (for example, at least a 10% reduction, such as at least a 20%, 30% or 40% reduction, e.g. at least a 50% reduction). Compounds per se In a second aspect of the invention, there is provided a compound of formula (I) according to the first aspect of the invention, or a pharmaceutically acceptable salt thereof, with the proviso that the following compounds are excluded: (4-(ethoxymethyl)phenyl)(3-(7-methyl-4-(methylamino)-5,6,7,8- tetrahydropyrido[3,4-d]pyrimidin-2-yl)pyrrolidine-1-yl)methanone; [1,1'-biphenyl]-2-yl(3-(7-methyl-4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4- d]pyrimidin-2-yl)pyrrolidin-1-yl)methanone; [3-[7-methyl-4-(methylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-2- yl]pyrrolidin-1-yl]-[4-(4-methyl-1-piperidyl)phenyl]methanone; 1-(4-(3-(7-methyl-4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2- yl)pyrrolidine-1-carbonyl)phenyl)pyrrolidin-2-one; [1,1'-biphenyl]-2-yl(3-(6-methyl-4-(methylamino)-5,6,7,8-tetrahydropyrido[4,3- d]pyrimidin-2-yl)pyrrolidin-1-yl)methanone; and 1-(3-(3-(6-methyl-4-(methylamino)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2- yl)pyrrolidine-1-carbonyl)phenyl)pyrrolidin-2-one. In some embodiments, the compound of formula (I) is not any of the following: . For the avoidance of doubt, the compounds per se of the second aspect of the invention, may have any of the features disclosed for the first aspect of the invention (and particular embodiments thereof). Particular compounds of the second aspect of the invention that may be mentioned include: [3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl]pyrrolidin-1-yl]- [4-(4-methyl-1-piperidyl)phenyl]methanone; [3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl]pyrrolidin-1-yl]- (4-pentylphenyl)methanone; (4-butylphenyl)-[3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2- yl]pyrrolidin-1-yl]methanone; [3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl]pyrrolidin-1-yl]- (4-propylphenyl)methanone; (4-ethylphenyl)-[3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2- yl]pyrrolidin-1-yl]methanone; [3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl]pyrrolidin-1-yl]- (2-naphthyl)methanone; (4-butoxyphenyl)-[3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2- yl]pyrrolidin-1-yl]methanone; [3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl]pyrrolidin-1-yl]- (4-phenylphenyl)methanone; (4-cyclohexylphenyl)-[3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin- 2-yl]pyrrolidin-1-yl]methanone; [4-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl]piperazin-1-yl]- [4-(4-methyl-1-piperidyl)phenyl]methanone; [3-[4-(dimethylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl]pyrrolidin-1- yl]-[4-(4-methyl-1-piperidyl)phenyl]methanone; N-methyl-2-[1-(4-phenylphenyl)sulfonylpyrrolidin-3-yl]-5,6,7,8- tetrahydropyrido[3,4-d]pyrimidin-4-amine; 2-[1-(4-butylphenyl)sulfonylpyrrolidin-3-yl]-N-methyl-5,6,7,8-tetrahydropyrido[3,4- d]pyrimidin-4-amine; 3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl]-N-(4- phenylphenyl)pyrrolidine-1-carboxamide; N-(4-butylphenyl)-3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2- yl]pyrrolidine-1-carboxamide; [3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-yl]pyrrolidin-1-yl]- [4-(4-methyl-1-piperidyl)phenyl]methanone; [4-(4-methoxy-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)piperazin-1-yl]-[4-(4- methyl-1-piperidyl)phenyl]methanone; and [4-[4-(dimethylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl]piperazin-1- yl]-[4-(4-methyl-1-piperidyl)phenyl]methanone; and pharmaceutically acceptable salts thereof. Pharmaceutical compositions As described herein, compounds of the first and, therefore, the second aspects of the invention are useful as pharmaceuticals. Such compounds may be administered alone or may be administered by way of known pharmaceutical compositions / formulations. In a third aspect, there is provided a pharmaceutical composition comprising a compound as defined in the first aspect of the invention, and optionally one or more pharmaceutically acceptable adjuvant, diluent and / or carrier. The skilled person will understand that references herein to compounds of the first aspect of the invention being for particular uses (and, similarly, to uses and methods of use relating to compounds of the invention) may also apply to pharmaceutical compositions comprising compounds of the invention as described herein. In a fourth aspect of the invention, there is provided a pharmaceutical composition for use in the prevention or treatment of infection with an enveloped virus (such as coronavirus) comprising a compound as defined in the first aspect of the invention, and optionally one or more pharmaceutically acceptable adjuvant, diluent and / or carrier. The skilled person will understand that compounds of the first (and, therefore, second and third) aspect of the invention may act systemically and / or locally (i.e. at a particular site). The skilled person will understand that compounds and compositions as described in the first to fourth aspects of the invention will normally be administered orally, intravenously, subcutaneously, buccally, rectally, dermally, nasally, tracheally, bronchially, sublingually, intranasally, topically, by any other parenteral route or via inhalation, in a pharmaceutically acceptable dosage form. Pharmaceutical compositions as described herein will include compositions in the form of tablets, capsules or elixirs for oral administration, suppositories for rectal administration, sterile solutions or suspensions for parenteral or intramuscular administration, and the like. Alternatively, particularly where such compounds of the invention act locally, pharmaceutical compositions may be formulated for topical administration. Thus, in particular embodiments of the third and fourth aspects of the invention, the pharmaceutical formulation is provided in a pharmaceutically acceptable dosage form, including tablets or capsules, liquid forms to be taken orally or by injection, suppositories, creams, gels, foams, inhalants (e.g. to be applied intranasally), or forms suitable for topical administration. For the avoidance of doubt, in such embodiments, compounds of the invention may be present as a solid (e.g. a solid dispersion), liquid (e.g. in solution) or in other forms, such as in the form of micelles. For example, in the preparation of pharmaceutical formulations for oral administration, the compound may be mixed with solid, powdered ingredients such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose derivatives, gelatin, or another suitable ingredient, as well as with disintegrating agents and lubricating agents such as magnesium stearate, calcium stearate, sodium stearyl fumarate and polyethylene glycol waxes. The mixture may then be processed into granules or compressed into tablets. Soft gelatin capsules may be prepared with capsules containing one or more active compounds (e.g. compounds of the first and, therefore, second and third aspects of the invention, and optionally additional therapeutic agents), together with, for example, vegetable oil, fat, or other suitable vehicle for soft gelatin capsules. Similarly, hard gelatine capsules may contain such compound(s) in combination with solid powdered ingredients such as lactose, saccharose, sorbitol, mannitol, potato starch, corn starch, amylopectin, cellulose derivatives or gelatin. Dosage units for rectal administration may be prepared (i) in the form of suppositories which contain the compound(s) mixed with a neutral fat base; (ii) in the form of a gelatin rectal capsule which contains the active substance in a mixture with a vegetable oil, paraffin oil, or other suitable vehicle for gelatin rectal capsules; (iii) in the form of a ready-made micro enema; or (iv) in the form of a dry micro enema formulation to be reconstituted in a suitable solvent just prior to administration. Liquid preparations for oral administration may be prepared in the form of syrups or suspensions, e.g. solutions or suspensions, containing the compound(s) and the remainder of the formulation consisting of sugar or sugar alcohols, and a mixture of ethanol, water, glycerol, propylene glycol and polyethylene glycol. If desired, such liquid preparations may contain colouring agents, flavouring agents, saccharine and carboxymethyl cellulose or other thickening agent. Liquid preparations for oral administration may also be prepared in the form of a dry powder to be reconstituted with a suitable solvent prior to use. Solutions for parenteral administration may be prepared as a solution of the compound(s) in a pharmaceutically acceptable solvent. These solutions may also contain stabilizing ingredients and / or buffering ingredients and are dispensed into unit doses in the form of ampoules or vials. Solutions for parenteral administration may also be prepared as a dry preparation to be reconstituted with a suitable solvent extemporaneously before use. The skilled person will understand that compounds of the invention, and pharmaceutically-acceptable salts thereof, may be administered (for example, as formulations as described hereinabove) at varying doses, with suitable doses being readily determined by one of skill in the art. Oral, pulmonary and topical dosages (and subcutaneous dosages, although these dosages may be relatively lower) may range from between about 0.01 μg / kg of body weight per day (μg / kg / day) to about 200 μg / kg / day, preferably about 0.01 to about 10 μg / kg / day, and more preferably about 0.1 to about 5.0 μg / kg / day. For example, when administered orally, treatment with such compounds may comprise administration of a formulations typically containing between about 0.01 μg to about 2000 mg, for example between about 0.1 μg to about 500 mg, or between 1 μg to about 100 mg (e.g. about 20 μg to about 80 mg), of the active ingredient(s). When administered intravenously, the most preferred doses will range from about 0.001 to about 10 μg / kg / hour during constant rate infusion. Advantageously, treatment may comprise administration of such compounds and compositions in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily (e.g. twice daily with reference to the doses described herein, such as a dose of 10 mg, 20 mg, 30 mg or 40 mg twice daily, or 10 μg, 20 μg, 30 μg or 40 μg twice daily). In any event, the skilled person (e.g. the physician) will be able to determine the actual dosage which will be most suitable for an individual patient, which is likely to vary with the route of administration, the type and severity of the condition that is to be treated, as well as the species, age, weight, sex, renal function, hepatic function and response of the particular patient to be treated. The above-mentioned dosages are exemplary of the average case; there can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention. As described herein above, the skilled person will understand that treatment with compounds of the first aspect of the invention may further comprise (i.e. be combined with) further (i.e. additional / other) treatment(s) for the same condition. In particular, treatment with compounds of the invention may be combined with other means for the treatment or prevention of an infection with an enveloped virus. In particular embodiments of the third and fourth aspects of the invention, the pharmaceutical composition may further comprise one or more additional (i.e. other) therapeutic agent. In more particular embodiments, the one or more additional therapeutic agent is an agent for the treatment or prevention of an infection with an enveloped virus, such as abacavir, lamivudine, rilpivirine, lopinavir, elvitegravir, enfuvirtide, lenacapavir, fostemsavir, maraviroc, remdesivir or paxlovid. The skilled person will understand that combinations of therapeutic agents may also described as a combination product and / or provided as a kit-of-parts. In a fifth aspect of the invention, there is provided a combination product comprising: (A) a compound as defined in the first (or second) aspect of the invention; and (B) one or more additional therapeutic agent, wherein each of components (A) and (B) is formulated in admixture, optionally with one or more a pharmaceutically-acceptable adjuvant, diluent or carrier. In a sixth aspect of the invention, there is provided a kit-of-parts comprising: (a) a compound as defined in the first (or second) aspect of the invention, (or a pharmaceutical composition comprising the same) or a pharmaceutical composition as defined in the third or fourth aspect of the invention; and (b) one or more other therapeutic agent, optionally in admixture with one or more pharmaceutically-acceptable adjuvant, diluent or carrier, which components (a) and (b) are each provided in a form that is suitable for administration in conjunction with the other. In particular embodiments (e.g. of the fifth and sixth aspects of the invention), the additional therapeutic agent is a therapeutic agent that is useful for the prevention or treatment of an infection with an enveloped virus (e.g. coronavirus), as known to those skilled in the art (such as those described herein). Preparation of compounds / compositions Pharmaceutical compositions / formulations, combination products and kits as described herein may be prepared in accordance with standard and / or accepted pharmaceutical practice. Thus, in a further aspect of the invention there is provided a process for the preparation of a pharmaceutical composition / formulation, as hereinbefore defined, which process comprises bringing into association a compound of the invention, as hereinbefore defined, with one or more pharmaceutically-acceptable adjuvant, diluent or carrier. In further aspects of the invention, there is provided a process for the preparation of a combination product or kit-of-parts as hereinbefore defined, which process comprises bringing into association a compound of the invention, as hereinbefore defined, or a pharmaceutically acceptable salt thereof with the other therapeutic agent that is useful in the treatment of an infection with an enveloped virus (e.g. coronavirus), and at least one pharmaceutically-acceptable adjuvant, diluent or carrier. As used herein, references to bringing into association will mean that the two components are rendered suitable for administration in conjunction with each other. Thus, in relation to the process for the preparation of a kit of parts as hereinbefore defined, by bringing the two components “into association with” each other, we include that the two components of the kit of parts may be: (i) provided as separate formulations (i.e. independently of one another), which are subsequently brought together for use in conjunction with each other in combination therapy; or (ii) packaged and presented together as separate components of a “combination pack” for use in conjunction with each other in combination therapy. Compounds as defined in the first aspect of the invention (i.e. compounds of the invention) may be prepared in accordance with techniques that are well known to those skilled in the art, such as those described in the examples provided hereinafter. For example, there is provided a process for the preparation of a compound of formula I, or a pharmaceutically acceptable salt thereof, which process comprises: (i) where L represents -C(O)- or -S(O)2-, reaction of a compound of formula II wherein X, Y, Z, R2and m are as defined herein, with a compound of formula III wherein R1and n are as defined herein, and wherein RX1represents a suitable leaving group, under conditions known to those skilled in the art; (ii) where L represents -NHC(O)-, reaction of a compound of formula II, wherein X, Y, Z, R2and m are as defined herein, with a compound of formula IV wherein R1and n are as defined herein, under conditions known to those skilled in the art. (iii) where Y represents NH, reaction of a compound of formula V, wherein R1, n, m, and L are as defined herein, with a compound of formula VI wherein R2, X and Z are as defined herein, wherein when representing nitrogen, X or Z are further attached to a suitable protecting group, and RX2represents a suitable halide, under conditions known to those skilled in the art. Description of the Figures Figure 1: Antiviral effect of Example 11 against SARS-CoV-2 Spike-pseudotyped lentivirus. (A) Exemplary images showing cell nuclei in gray and infected cells in white. (B) Quantification of a dose-dependent antiviral effect. The infection rate was normalized to DMSO sample (vehicle-treated infected cells). E-64d, Cathepsin inhibitor, was used as a positive control. Spike-PV, Spike-pseudovirus; GFP, Green Fluorescent Protein. The compound of Example 11 is indicated in Figure 1 as “Cov-1”. Figure 2: Dose-dependent antiviral effect of Example 11 on SARS-CoV-2 variants in Vero E6 (A) and A549-ACE2 (B) cells. The infection rate was normalized to DMSO sample (vehicle-treated infected cells). The compound of Example 11 is indicated in Figure 2 as “Cov-1”. Figure 3: Antiviral effect of Example 11 against SARS-CoV-2 in liver spheroids. Statistical analysis – ANOVA. Ns, non-significant. The compound of Example 11 is indicated in Figure 3 as “Cov-1”. Figure 4: Antiviral activity of Example 11 against Monkeypox and TBEV viruses. The infection rate was normalized to DMSO sample (vehicle-treated infected cells). The compound of Example 11 is indicated in Figure 4 as “Cov-1”. Examples The present invention is illustrated by way of the following examples. Chemicals and reagents were obtained from commercial suppliers and were used as received unless otherwise stated. All reactions involving moisture sensitive reagents were performed in oven or flame dried glassware under a positive pressure of nitrogen or argon. Abbreviations Abbreviations as used herein will be known to those skilled in the art. In particular, the following abbreviations may be used herein. DCM dichloromethane EtOAc ethyl acetate TFA trifluoro acetic acid HATU 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate rt room temperature on over night Methods and materials ^1H NMR spectra were recorded in CDCl3 (internal standard: 7.26 ppm), DMSO-d6 (internal standard: 2.50 ppm) or methanol-d4 (internal standard: 3.31 ppm) on a Bruker DRX-400 MHz spectrometer. Coupling constants (J) are quoted in hertz (Hz) and are recorded to the nearest 0.1 Hz. The following abbreviations are used: s, singlet; d, doublet; dd, doublet of doublets; t, triplet; m, multiplet; q, quartet; and br, broad ^ Flash column chromatography ZDV^SHUIRUPHG^XVLQJ^VLOLFD^JHO^^^^í^^^NjP^ ^ The purity of the tested compounds 1í19 is at least 95% as assessed by HPLC- UV at 214, 254, and 280 nm or by NMR (Exceptions are stated in the synthesis description). ^ The starting materials were commercially available. ^ $QDO\WLFDO^ 53 / &í06^ZDV^ SHUIRUPHG^XVLQJ^ D^+3 / &í06^$JLOHQW^+3^^^^^^ V\VWHP^ 6110 mass VSHFWURPHWHU^ ZLWK^ HOHFWURVSUD\^ LRQL]DWLRQ^ ^(6,^^^^ +3 / &í06 methods were the following. Method 1: Waters XBridge C18 3.5 NjP^ FROXPQ^ ^^^^^ PP^ î^ ^^^ PP^^^ ^^^^ PLQ^ JUDGLHQW^ PRELOH^ SKDVH >0H&1@^>^^^ P0^ 1+^^ +&2^^+^ ^^ 2@^0HWKRG^ ^^^ 0H&1^ &^^^ ^^^^ NjP FROXPQ^ ^^^^^ PP^ î^ ^^^ PP^, mobile phase [0.1% TFA / MeCN] / [0.1% TFA / H2 O] on a Water micro mass ZQ 2000 using positive and negative electrospray ionization. Example compounds In the event that there is a discrepancy between nomenclature and the structure of compounds as depicted graphically, it is the latter that presides (unless contradicted by any experimental details that may be given and / or unless it is clear from the context). Synthesis of intermediates INTERMEDIATE 1 - tert-Butyl 2-chloro-4-(methylamino)-6,8-dihydro-5H-pyrido[3,4- d]pyrimidine-7-carboxylate Methylamine in water (0.8 mL, 40%) was added to a solution of tert-butyl 2,4-dichloro- 6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxylate (608 mg, 2.0 mmol) in methanol (1 mL) at used 0°C and stirred for 2h in ice and then at rt 2h. The solid was filtered and washed with aqueous methanol to give an off-white solid (550 mg). Recrystallisation from methanol (5 mL) and water (1mL) gave the title compound as an off-white solid. Yield 450 mg.1H NMR (400 MHz, DMSO-d6) į ppm 1.41 (s, 9 H) 2.35 (t, J=5.50 Hz, 2 H) 2.83 (d, J=4.50 Hz, 3 H) 3.57 (t, J=5.32 Hz, 2 H) 4.24 (br. s., 2 H) 7.38 (br. s., 1 H). MS (ESI+) for C13H19ClN4O2 Calc mass 298.12, Measured mass 299.1 (M+1). INTERMEDIATE 2 - tert-Butyl 2-(1-benzylpyrrolidin-3-yl)-4-(methylamino)-6,8- Step 1 Tetrakis(triphenylphosphine)-palladium(0) (29 mg, 25 μmol) was added to a stirred mixture of (INTERMEDIATE 1) (150 mg, 0.5 mmol), 2,4,6-trivinylcyclotriboroxane pyridine complex CAS 442850-89-7 (60 mg, 0.25 mmol) and Na2CO3(212mg, 4 mmol) in toluene (750 μL), ethanol (750 μL) and water (250 μL) was under N2. The mixture was stirred at 100°C on. Water (50 mL) was added, and the mixture was extracted with EtOAc (50 mL x 2). The combined organic layers were washed with water, brine (100 mL), dried (Na2SO4) and concentrated and used directly in step 2. Yield 145 mg Step 2 The material from step 1 was treated with N-(methoxymethyl)-1-phenyl- N(trimethylsilylmethyl)methanamine (700 μL, ca 5 eq) and TFA (200 μL, ca 5 eq) in DCM (10 mL) at 0°C for 2h then rt on. The reaction was diluted with DCM and washed with Na2CO3 (aq sat) and purified by silica gel chromatography eluded by a gradient DCM:methanol:NH3 (aq) 19:1:0.1 to 9:1:0.1. Yield 0.20 g1H NMR (400 MHz, METHANOL-d4) į ppm 1.47 (s, 9 H) 2.18 - 2.26 (m, 2 H) 2.39 (t, J=5.88 Hz, 2 H) 2.61 - 2.71 (m, 1 H) 2.79 (dd, J=9.38, 8.38 Hz, 1 H) 2.88 (ddd, J=9.22, 6.91, 5.38 Hz, 1 H) 2.97 (s, 3 H) 3.10 (t, J=8.82 Hz, 1 H) 3.42 (quin, J=8.16 Hz, 1 H) 3.62 - 3.69 (m, 3 H) 3.69 - 3.74 (m, 1 H) 4.35 (s, 2 H) 7.21 - 7.27 (m, 1 H) 7.28 - 7.38 (m, 4 H) MS (ESI+) for C24H33N5O2Calc mass 423.26, Measured mass 424.2 (M+1) INTERMEDIATE 3 - tert-Butyl 4-(methylamino)-2-pyrrolidin-3-yl-6,8-dihydro-5H- tert-Butyl 2-(1-benzylpyrrolidin-3-yl)-4-(methylamino)-6,8-dihydro-5H-pyrido[3,4- d]pyrimidine-7-carboxylate (INTERMEDIATE 2) (320 mg, 0.76 mmol) was hydrogenated over palladium on charcoal (10%, 320 mg) in EtOAc (35 mL) at rt for 3 days. The reaction mixture was filterred through celite, washing the solid with methanol and the solvents were evaporated. The product was purified by silica gel chromatography eluded with DCM:methanol:NH3(aq) 85:15:1 to give the title compound. Yield 115 mg.1H NMR (400 MHz, DMSO-d6) į ppm 1.41 (s, 9 H) 1.92 - 2.06 (m, 2 H) 2.33 (t, J=5.19 Hz, 2 H) 2.81 - 2.93 (m, 4 H) 2.99 (d, J=6.13 Hz, 2 H) 3.05 - 3.24 (m, 2 H) 3.56 (br. s., 2 H) 4.23 (s, 2 H) 5.75 (s, 1 H) 6.63 - 6.92 (m, 1 H) MS (ESI+) for C17H27N2O2Calc mass 333.22 Measured mass 335.1 (M+1) Triethylamine (27 μL, 0.20 mmol) was added at room temperature to a stirred solution of tert-butyl 4-(methylamino)-2-pyrrolidin-3-yl-6,8-dihydro-5H-pyrido[3,4- d]pyrimidine-7-carboxylate (INTERMEDIATE 3) (42 mg, 0.13 mmol), 4-(4-methyl-1- piperidyl)benzoic acid (33 mg, 0.15 mmol) and HATU (49 mg, 0.13mmol) in DMF (2mL). After 1h the reaction was and diluted with water and methanol and purified by preparative HPLC to give the product as a light-yellow oil. Yield 50 mg.1H NMR (400 MHz, DMSO-d6) į ppm 0.92 (d, J=6.50 Hz, 3 H) 1.09 - 1.28 (m, 2 H) 1.41 (s, 9 H) 1.47 - 1.60 (m, 1 H) 1.62 - 1.72 (m, 2 H) 2.09 - 2.26 (m, 2 H) 2.27 - 2.41 (m, 2 H) 2.62 - 2.76 (m, 2 H) 2.77 - 2.91 (m, 3 H) 3.44 - 3.68 (m, 5 H) 3.70 - 3.87 (m, 4 H) 4.16 - 4.32 (m, 2 H) 6.71 - 6.86 (m, 1 H) 6.87 - 6.95 (m, 2 H) 7.35 - 7.45 (m, 2 H). MS (ESI+) for C30H42N6O3Calc mass 534.33 Measured mass 535.3 (M+1). INTERMEDIATE 5 - tert-Butyl 2-chloro-4-(dimethylamino)-6,8-dihydro-5H-pyrido[3,4- tert-Butyl 2,4-dichloro-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxylate (507 mg, 1.7 mmol) was added to solution of dimethylamine in tetrahydrofuran (10 mL, 2M) at 0°C and stirred for 1h. Another lot of tert-butyl 2,4-dichloro-6,8-dihydro-5H- pyrido[3,4-d]pyrimidine-7-carboxylate (406 mg, 1.3 mmol) was added and the reaction was stirred one more h. The solvent was evaporated, and DCM and water was added, and the organic phase was dried (Na2SO4) and evaporated to give a yellow oil. Crystallization from methanol (ca 2mL) and water added during stirring (ca 1mL) gave the product as an off-white solid. Yield 0.59 g1H NMR (400 MHz, DMSO-d6) į ppm 1.43 (s, 9 H) 2.75 (t, J=5.25 Hz, 2 H) 3.06 (s, 6 H) 3.44 (br. s., 2 H) 4.31 (br. s., 2 H). MS (ESI+) for C14H21ClN4O2Calc mass 312.14 Measured mass 313.1(M+1). INTERMEDIATE 6 - tert-Butyl 2-(1- dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxylate The reaction was performed as INTERMEDIATE 2 using tert-Butyl 2-chloro-4- (dimethylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxylate (INTERMEDIATE 5). Yellow oil. Yield 0.32 g. MS (ESI+) for C25H35N5O2 Calc mass 437.28 Measured mass 438.3 (M+1). INTERMEDIATE 7 - tert-butyl 4-(methylamino)-2-piperazin-1-yl-6,8-dihydro-5H- pyrido[3,4-d]pyrimidine-7-carboxylate tert-Butyl 2-chloro-4-(methylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7- carboxylate (INTERMEDIATE 1) (45 mg, 0.15 mmol) was added to a melt of piperazine (200 mg, 2.3 mmol, at 130°C and stirred for 15 minutes. After 30 minuter the reaction was cooled, water was added and extracted with EtOAc. The organic phase was washed with brine, dried (Na2SO4) and evaporated. The material was purified by silica gel chromatography eluded with DCM:methanol:NH3(conc, aq) 9:1:0.1. Yield 32 mg. MS (ESI+) for C17H28N6O2Calc mass 348.23 Measured mass 349.2 (M+1). INTERMEDIATE 8 - tert-Butyl 2-chloro-4-(methylamino)-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine-6-carboxylate Methylamine in water (0.4 mL, 40%) was added to a solution of tert-butyl 2,4-dichloro- 7,8-dihydro-5H-pyrido[4,3-d]pyrimidine-6-carboxylate (0.30 g, 1.0 mmol) in methanol (0.5 mL) at 0°C and stirred for 2h in ice and then at rt 2h. The solvents were evaporated and the product purifies by silica gel chromatography eluded with an gradient of isohexane:EtOAc 3:1 to 1:1 to give the product as an oil. Yield 240 mg.1H NMR (400 MHz, METHANOL-d4) į ppm 1.49 (s, 9 H) 2.66 (t, J=5.88 Hz, 2 H) 2.96 (s, 3 H) 3.68 (t, J=5.75 Hz, 2 H) 4.22 (br. s., 2 H). MS (ESI+) for C13H19ClN4O2 Calc mass 298.12 Measured mass 299.1 (M+1). INTERMEDIATE 9 - tert-butyl 2-chloro-4-methoxy-6,8-dihydro-5H-pyrido[3,4- d]pyrimidine-7-carboxylate tert-Butyl 2,4-dichloro-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxylate (150 mg, 0.50 mmol) was dissolved in methanol (3 mL) and chilled in an ice bath. Sodium methoxide solution was added dropwise and the reaction was stirred for 2h. The solvents were evaporated and then extraction with water and EtOAc. The organic phase was dried (Na2SO4) and evaporated to give a clear oil. Yield 131 mg. NMR (400 MHz, CHLOROFORM-d) į ppm 1.45 - 1.47 (m, 9 H) 2.63 (t, J=5.32 Hz, 2 H) 3.65 (t, J=5.82 Hz, 2 H) 4.02 (s, 3 H) 4.51 (s, 2 H). MS (ESI+) for C13H18ClN3O3Calc mass 299.10 Measured mass 300.1 (M+1). INTERMEDIATE 10 - 1-[4-(4-methylpiperidin-1-yl)benzoyl]piperazine hydrochloride A solution of tert-butyl piperazine-1-carboxylate (93 mg, 0.50 mmol), 4-(4-methyl-1- piperidyl)benzoic acid (110 mg, 0.05mmol), HATU (190 mg, 0.50 mmol) and triethylamine (0.11mL, 0.8 mmol) in DMF (2mL) was stirred at rt on. NaHCO3 (aq sat) was added, and the product was extracted with DCM. The organic phase was evaporated and treated with 2M HCl at 100°C for 1h. The reaction was made basic with NaHCO3 and extracted with DCM, dried (Na2SO4) and evaporated. The material was dissolved in 1 M HCl and evaporated to give the hydrochloric salt that was treated with a small amount of methanol and then gradually during stirring adding EtOAc gave the product as a pink solid after filtering and drying. Yield 116 mg. MS (ESI+) for C17H25N3O Calc mass 287.20 Measured mass 288.1 (M+1). INTERMEDIATE 11 - tert-Butyl 4-(dimethylamino)-2-pyrrolidin-3-yl-6,8-dihydro-5H- pyrido[3,4-d]pyrimidine-7-carboxylate A solution of tert-butyl 2-(1-benzylpyrrolidin-3-yl)-4-(dimethylamino)-6,8-dihydro- 5H-pyrido[3,4-d]pyrimidine-7-carboxylate (INTERMEDIATE 6) (150 mg ,0.34 mmol) in acetic acid (10 mL) was hydrogenated over palladium on charcoal (300 mg,10%, wet (67% water content) on.The mixture was filtered through celite, washed with methanol and evaporated. The residue was redissolved in a small volume of water and basified with NaHCO3 (sat aq) and extracted with EtOAc. The organic phase was evaporated and purified by silica gel column chromatography eluded with DCM:methanol:NH3 (aq) 85:15:1. Yield 65mg. MS (ESI+) for C18H29N5O2 Calc mass 347.23 Measured mass 348.2 (M+1). Example 1 - [3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2- yl]pyrrolidin-1-yl]-[4-(4-methyl-1-piperidyl)phenyl]methanone; hydrochloride tert-Butyl 4-(methylamino)-2-[1-[4-(4-methyl-1-piperidyl)benzoyl]pyrrolidin-3-yl]- 6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxylate (INTERMEDIATE 4), (37mg, 0.07mmol) was treated with HCl (aq, 1M, 2mL) at reflux for 5 minutes and the solvent was evaporated leaving the HCl salt as a solid (33 mg). The material was further purified by preparative HPLC. The pure fractions were evaporated and dried in vacuum. The product was dissolved in 1 M HCl and evaporated to give the HCl salt as a white solid after drying in vacuum. Yield 28 mg.1H NMR (400 MHz, METHANOL-d4) į ppm 1.11 (dd, J=6.13, 2.50 Hz, 3 H) 1.70 - 1.86 (m, 2 H) 1.93 (br. s., 1 H) 2.08 (d, J=13.88 Hz, 2 H) 2.33 - 2.63 (m, 2 H) 2.74 - 2.88 (m, 2 H) 3.16 (d, J=1.00 Hz, 3 H) 3.56 - 3.85 (m, 9 H) 3.85 - 4.19 (m, 3 H) 4.34 - 4.49 (m, 2 H) 7.61 - 8.06 (m, 4 H). MS (ESI+) for C25H34N6O Calc mass 434.28 Measured mass 435.2 (M+1). Example 2 - [3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2- yl]pyrrolidin-1-yl]-(4-pentylphenyl)methanone tert-butyl 4-(methylamino)-2-pyrrolidin-3-yl-6,8-dihydro-5H-pyrido[3,4- d]pyrimidine-7-carboxylate (INTERMEDIATE 3) (17mg, 0.050mmol) and 4- pentylbenzoyl chloride (12 mg, 0.055mmol) and triethylamine (11μL, 0.08mmol) were stirred at 1h at room temperature in DCM (1mL). The solvent was evaporated and 1M HCl (11mL) was added and stirred for 30 min at 80°C and the solvent was evaporated. The pure product was achieved after silica gel chromatography eluded with DCM:methanol:NH3(aq, conc) 90:10:1. Yield 11 mg. 1H NMR (400 MHz, CHLOROFORM-d) į ppm 0.81 (td, J=6.63, 4.00 Hz, 3 H) 1.17 - 1.30 (m, 2 H) 1.53 (dq, J=14.63, 7.30 Hz, 2 H) 2.11 - 2.21 (m, 1 H) 2.22 - 2.38 (m, 3 H) 2.54 (q, J=7.59 Hz, 2 H) 2.85 (br. s., 1 H) 2.94 (dd, J=14.95, 4.69 Hz, 4 H) 3.11 (dt, J=15.01, 5.82 Hz, 2 H) 3.33 (quin, J=7.10 Hz, 1 H) 3.40 - 3.54 (m, 1 H) 3.55 - 3.86 (m, 5 H) 3.89 - 4.05 (m, 1 H) 4.62 - 4.82 (m, 1 H) 7.11 (t, J=8.32 Hz, 2 H) 7.38 (d, J=7.88 Hz, 2 H). MS (ESI+) for C24H33N5O Calc mass 407.27 Measured mass 408.2 (M+1). Example 3 - (4-butylphenyl)-[3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4- d]pyrimidin-2-yl]pyrrolidin-1-yl]methanone The reaction was performed as Example 2, using 4-butylbenzoyl chloride. Yield 12 mg.1H NMR (400 MHz, CHLOROFORM-d) į ppm 0.88 - 0.96 (m, 3 H) 1.34 (dquin, J=14.50, 7.16, 7.16, 7.16, 7.16 Hz, 2 H) 1.59 (sxt, J=7.53 Hz, 2 H) 2.20 - 2.46 (m, 4 H) 2.62 (q, J=7.59 Hz, 2 H) 2.97 - 3.07 (m, 3 H) 3.16 (dt, J=12.10, 5.89 Hz, 2 H) 3.41 (quin, J=7.19 Hz, 1 H) 3.48 - 3.61 (m, 1 H) 3.63 - 3.92 (m, 5 H) 3.98 - 4.11 (m, 1 H) 4.60 - 4.72 (m, 1 H) 7.18 (t, J=8.38 Hz, 2 H) 7.45 (d, J=8.13 Hz, 2 H)MS (ESI+) for C23H31N5O Calc mass 393.25 . MS (ESI+) for C23H31N5O Calc mass 393.25 Measured mass 394.2 (M+1). Example 4 - [3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2- yl]pyrrolidin-1-yl]-(4-propylphenyl)methanone The reaction was performed as Example 2, using 4-propylbenzoyl chloride. Yield 10 mg.1H NMR (400 MHz, CHLOROFORM-d) į ppm 0.88 - 0.99 (m, 3 H) 1.63 (spt, J=7.40 Hz, 2 H) 2.19 - 2.45 (m, 4 H) 2.59 (q, J=7.59 Hz, 2 H) 2.98 - 3.07 (m, 3 H) 3.15 (dt, J=11.44, 5.78 Hz, 2 H) 3.41 (quin, J=7.19 Hz, 1 H) 3.46 - 3.61 (m, 1 H) 3.65 - 3.92 (m, 5 H) 3.97 - 4.12 (m, 1 H) 4.54 - 4.66 (m, 1 H) 7.18 (t, J=8.38 Hz, 2 H) 7.46 (d, J=8.13 Hz, 2 H). MS (ESI+) for C22H29N5O Calc mass 379.51 Measured mass 380.2 (M+1). Example 5 - (4-ethylphenyl)-[3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4- d]pyrimidin-2-yl]pyrrolidin-1-yl]methanone The reaction was done as described in Example 2 using 4-ethylbenzoyl chloride. Yield 11 mg.1H NMR (400 MHz, CHLOROFORM-d) į ppm 1.23 (q, J=7.55 Hz, 3 H) 2.20 - 2.43 (m, 4 H) 2.66 (quin, J=7.60 Hz, 2 H) 2.98 - 3.07 (m, 3 H) 3.15 (dt, J=11.32, 5.60 Hz, 2 H) 3.41 (quin, J=7.19 Hz, 1 H) 3.48 - 3.60 (m, 1 H) 3.66 - 3.92 (m, 5 H) 3.98 - 4.11 (m, 1 H) 4.54 - 4.65 (m, 1 H) 7.21 (t, J=8.38 Hz, 2 H) 7.47 (d, J=8.13 Hz, 2 H). MS (ESI+) for C21H27N5O Calc mass 365.22 Measured mass 366.2 (M+1). The reaction was done as described in Example 2 using naphthalene-2-carbonyl chloride. Yield 10 mg.1H NMR (400 MHz, CHLOROFORM-d) į ppm 1.73 - 2.01 (m, 2 H) 2.23 - 2.48 (m, 4 H) 3.00 (d, J=4.88 Hz, 2 H) 3.07 (d, J=4.75 Hz, 1 H) 3.14 (dt, J=18.07, 5.78 Hz, 2 H) 3.39 - 3.50 (m, 1 H) 3.52 - 3.67 (m, 1 H) 3.70 - 3.99 (m, 5 H) 4.12 (qd, J=12.42, 7.63 Hz, 1 H) 4.60 (dd, J=17.57, 4.32 Hz, 1 H) 7.47 - 7.57 (m, 2 H) 7.64 (d, J=8.51 Hz, 1 H) 7.80 - 7.91 (m, 3 H) 8.03 (s, 1 H). MS (ESI+) for C23H25N5O Calc mass 387.21 Measured mass 388.2 (M+1). The reaction was done as described in Example 2 using 4-butoxybenzoyl chloride. Yield 15 mg.1H NMR (400 MHz, CHLOROFORM-d) į ppm 0.92 - 1.03 (m, 3 H) 1.41 - 1.55 (m, 2 H) 1.71 - 1.81 (m, 2 H) 2.20 - 2.43 (m, 4 H) 2.96 - 3.07 (m, 3 H) 3.15 (d, J=4.88 Hz, 2 H) 3.41 (quin, J=7.16 Hz, 1 H) 3.47 - 3.64 (m, 1 H) 3.66 - 3.77 (m, 1 H) 3.83 (dd, J=11.32, 4.06 Hz, 3 H) 3.88 - 4.11 (m, 4 H) 4.59 (d, J=4.50 Hz, 1 H) 6.82 - 6.93 (m, 2 H) 7.48 - 7.56 (m, 2 H). MS (ESI+) for C23H31N5O2Calc mass 409.25 Measured mass 410.2 (M+1). Example 8 - [3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2- yl]pyrrolidin-1-yl]-(4-phenylphenyl)methanone Triethyl amine (11 μL, 0.075 mmol) was added to a solution of tert-Butyl 4- (methylamino)-2-pyrrolidin-3-yl-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7- carboxylate (INTERMEDIATE 2) (17 mg, 0.050 mmol), 4-phenylbenzoic acid (11 mg, 0.055 mmol) and HATU (23mg, 0.060mmol) in DCM (2 mL) and stirred for 2h.The solvent was evaporated and the residue treated with HCl (aq, 1M, 1 mL) at 80°C for 30 min and the evaporated. After cooling, methanol (1 mL) and NaOH (2M, 0.25mL) were added and the mixture was purified by preparative basic HPLC. Yield 9mg.1H NMR (400 MHz, METHANOL-d4) į ppm 2.22 - 2.33 (m, 1 H) 2.33 - 2.47 (m, 3 H) 2.93 - 3.04 (m, 3 H) 3.10 (dt, J=15.26, 5.82 Hz, 2 H) 3.40 - 3.60 (m, 1 H) 3.64 - 3.81 (m, 3 H) 3.82 - 4.10 (m, 3 H) 7.34 - 7.42 (m, 1 H) 7.43 - 7.52 (m, 2 H) 7.61 - 7.69 (m, 4 H) 7.70 - 7.76 (m, 2 H). MS (ESI+) for C25H27N5O Calc mass 413.22 Measured mass 414.2 (M+1). Was done as Example 8 with 4-cyclohexylbenzoic acid. Yield 8 mg.1H NMR (400 MHz, METHANOL-d4) į ppm 1.23 - 1.38 (m, 1 H) 1.40 - 1.55 (m, 6 H) 1.73 - 1.83 (m, 1 H) 1.87 (d, J=8.25 Hz, 4 H) 2.37 (d, J=6.38 Hz, 4 H) 2.50 - 2.70 (m, 1 H) 2.92 - 3.03 (m, 3 H) 3.08 (s, 2 H) 3.36 - 3.57 (m, 1 H) 3.60 - 4.06 (m, 6 H) 7.32 (t, J=7.57 Hz, 2 H) 7.45 - 7.51 (m, 2 H) MS (ESI+) for C25H33N5O Calc mass 419.27 Measured mass 420.3 (M+1) yl]piperazin-1-yl]-[4-(4-methyl-1-piperidyl)phenyl]methanone Step 1 was done as in INTERMEDIATE 4 using tert-butyl 4-(methylamino)-2-piperazin- 1-yl-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxylate (INTERMEDIATE 7) and step 2 as Example 2. Yield 9 mg.1H NMR (400 MHz, CHLOROFORM-d) d ppm 0.98 (d, J=6.50 Hz, 3 H) 1.32 (qd, J=12.24, 3.94 Hz, 2 H) 1.50 - 1.62 (m, 1 H) 1.73 (d, J=11.88 Hz, 2 H) 1.97 (br. s., 2 H) 2.24 (t, J=5.50 Hz, 2 H) 2.77 (td, J=12.38, 2.50 Hz, 2 H) 2.98 (d, J=4.75 Hz, 3 H) 3.13 (br. s., 2 H) 3.54 - 3.91 (m, 12 H) 4.43 (d, J=4.75 Hz, 1 H) 6.89 (d, J=8.76 Hz, 2 H) 7.32 - 7.40 (m, 2 H). MS (ESI+) for C25H35N7O Calc mass 449.29 Measured mass 450.3 (M+1). A solution of [3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2- yl]pyrrolidin-1-yl]-[4-(4-methyl-1-piperidyl)phenyl]methanone;hydrochloride (EXAMPLE 1) (23 mg, 0,05 mmol), formaldehyde (30 μL, 1 mmol), sodium triacetoxyborohydride (0.21 g, 1 mmol) in 1,2 dichloroethane (5 mL) and methanol (1 mL). After 6h the reaction was worked up by adding DCM and NaOAc, The organic phase was evaporated and purified by prep HPLC gave a clear oil. Yield 8mg. ppm 0.94 - 1.01 (m, 3 H) 1.20 - 1.35 (m, 2 H) 1.56 (dt, J=6.82, 3.60 Hz, 1 H) 1.74 (d, J=12.88 Hz, 2 H) 2.19 - 2.39 (m, 2 H) 2.39 - 2.52 (m, 5 H) 2.70 - 2.82 (m, 4 H) 2.90 - 3.02 (m, 3 H) 3.35 - 3.55 (m, 3 H) 3.58 - 3.75 (m, 1 H) 3.75 - 3.85 (m, 3 H) 3.85 - 3.93 (m, 1 H) 3.93 - 4.04 (m, 1 H) 6.85 - 7.05 (m, 2 H) 7.46 (d, J=8.75 Hz, 2 H). MS (ESI+) for C25H34N6O Calc mass 448.30 Measured mass 449.3 (M+1). [3-[7-methyl-4-(methylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-2- yl]pyrrolidin-1-yl]-[4-(4-methyl-1-piperidyl)phenyl]methanone hydrochloride The HCL salt was achieved in the following way. [3-[7-methyl-4-(methylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-2- yl]pyrrolidin-1-yl]-[4-(4-methyl-1-piperidyl)phenyl]methanone (8mg) was dissolved in diethyl ether and stirred. HCl in diethyl ether was added and the mixture stirred for 3h at rt. The solid was isolated by centrifugation and the white material was dried in vacuum on. Yield 6 mg. tert-Butyl tert-butyl 4-(dimethylamino)-2-pyrrolidin-3-yl-6,8-dihydro-5H-pyrido[3,4- d]pyrimidine-7-carboxylate (INTERMEDIATE 11) (20mg, 0.058mmol), 4-(4-methyl-1- piperidyl)benzoic acid (15mg, 0.069mmol) and HATU (26mg, 0.069mmol) in DMF (0.5mL) and stirred overnight. HCl (aq, 2M, 0.25mL) was added to the reaction and was heated to 80° for 1h. After cooling, methanol (1mL) and NaOH (2M, 0.25mL) were added and the mixture was purified by prep basic HPLC. Yield 9mg1H NMR (400 MHz, CHLOROFORM-d) į ppm 0.97 (d, J=6.38 Hz, 3 H) 1.30 (q, J=12.22 Hz, 2 H) 1.44 - 1.62 (m, 1 H) 1.72 (d, J=12.63 Hz, 2 H) 2.12 - 2.41 (m, 2 H) 2.59 - 2.82 (m, 4 H) 2.91 - 3.12 (m, 8 H) 3.34 - 3.56 (m, 1 H) 3.58 - 4.09 (m, 9 H) 6.86 (d, J=8.13 Hz, 2 H) 7.49 (d, J=8.75 Hz, 2 H) MS (ESI+) for C26H36N6O Calc mass 448.30 Measured mass 449.3 (M+1) Example 13 - N-methyl-2-[1-(4-phenylphenyl)sulfonylpyrrolidin-3-yl]-5,6,7,8- tetrahydropyrido[3,4-d]pyrimidin-4-amine A solution of tert-butyl 4-(methylamino)-2-pyrrolidin-3-yl-6,8-dihydro-5H-pyrido[3,4- d]pyrimidine-7-carboxylate (INTERMEDIATE 3) (19mg, 0,057mmol), 4- phenylbenzenesulfonyl chloride (17mg, 0.068mmol) and triethylamine (12μL, 0.85mmol) in DCM (1mL) was stirred at rt for 2h. 2M aq HCl (0.25mL) was added and the mixture was heated to 80° for 1h with stirring. methanol (1mL) and the solution was made alkaline by adding 2M NaOH (0.25mL). The product was purified by prep basic HPLC. Yield 13 mg1H NMR (400 MHz, CHLOROFORM-d) į ppm 1.77 (br. s., 1 H) 2.13 - 2.29 (m, 4 H) 2.90 (d, J=4.88 Hz, 3 H) 3.09 (t, J=5.88 Hz, 2 H) 3.32 (quin, J=7.57 Hz, 1 H) 3.41 (dt, J=9.47, 7.27 Hz, 1 H) 3.56 (ddd, J=9.41, 7.54, 5.44 Hz, 1 H) 3.67 - 3.82 (m, 4 H) 4.48 (d, J=4.63 Hz, 1 H) 7.39 - 7.45 (m, 1 H) 7.46 - 7.52 (m, 2 H) 7.59 - 7.64 (m, 2 H) 7.67 - 7.73 (m, 2 H) 7.87 - 7.94 (m, 2 H) MS (ESI+) for C24H27N5O2S Calc mass 449.19 Measured mass 450.1 (M+1) Example 14 - 2-[1-(4-butylphenyl)sulfonylpyrrolidin-3-yl]-N-methyl-5,6,7,8- tetrahydropyrido[3,4-d]pyrimidin-4-amine The reaction was done as described in Example 13 using 4-butylbenzenesulfonyl chloride. Yield 10mg.1H NMR (400 MHz, CHLOROFORM-d) į ppm 0.92 - 0.98 (m, 3 H) 1.37 (dq, J=14.99, 7.38 Hz, 2 H) 1.57 - 1.67 (m, 2 H) 1.72 (br. s., 2 H) 2.11 - 2.21 (m, 2 H) 2.28 (t, J=5.82 Hz, 1 H) 2.64 - 2.71 (m, 2 H) 2.94 (d, J=4.75 Hz, 3 H) 3.14 (t, J=5.82 Hz, 2 H) 3.23 - 3.39 (m, 2 H) 3.47 - 3.56 (m, 1 H) 3.63 - 3.75 (m, 2 H) 3.78 (s, 2 H) 4.50 (d, J=4.50 Hz, 1 H) 7.30 (d, J=8.25 Hz, 2 H) 7.72 - 7.78 (m, 2 H) MS (ESI+) for C22H31N5O2S Calc mass 429.22 Measured mass 430.2 (M+1) Example 15 - 3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl]-N- (4-phenylphenyl)pyrrolidine-1-carboxamide Triethylamine was added to a solution of tert-butyl 4-(methylamino)-2-pyrrolidin-3-yl- 6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxylate (INTERMEDIATE 3) and 1- isocyanato-4-phenyl-benzene dissolved in DMF (0.5mL) and stirred at rt for 2h. 2M HCl (0.25mL) was added to the reaction and was heated to 80° for 1h. Methanol (1 mL) was added and neutralized with NaOH (2M, 0.25mL).The product was purified by preparative basic HPLC. Yield 3mg1H NMR (400 MHz, METHANOL-d4) į ppm 2.27 - 2.42 (m, 4 H) 2.98 (s, 3 H) 3.06 - 3.13 (m, 2 H) 3.43 - 3.52 (m, 1 H) 3.53 - 3.61 (m, 1 H) 3.75 (s, 3 H) 3.79 - 3.85 (m, 1 H) 3.87 - 3.94 (m, 1 H) 7.25 - 7.32 (m, 1 H) 7.40 (s, 2 H) 7.52 (d, J=2.75 Hz, 4 H) 7.56 - 7.61 (m, 2 H) MS (ESI+) for C25H28N6O Calc mass 428.23 Measured mass 429.2 (M+1) Example 16 - N-(4-butylphenyl)-3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4- d]pyrimidin-2-yl]pyrrolidine-1-carboxamide The reaction was done as described in Example 15 using 1-butyl-4-isocyanato- benzene. Yield 11mg1H NMR (400 MHz, CHLOROFORM-d) į ppm 0.91 (t, J=7.32 Hz, 3 H) 1.33 (dq, J=14.90, 7.37 Hz, 2 H) 1.50 - 1.62 (m, 2 H) 1.89 (br. s., 1 H) 2.27 - 2.40 (m, 4 H) 2.55 (t, J=7.69 Hz, 2 H) 3.02 (d, J=4.88 Hz, 3 H) 3.16 (br. s., 2 H) 3.48 - 3.58 (m, 2 H) 3.69 - 3.77 (m, 1 H) 3.78 - 3.92 (m, 4 H) 4.60 (d, J=4.50 Hz, 1 H) 6.17 (s, 1 H) 7.08 (d, J=8.38 Hz, 2 H) 7.28 - 7.34 (m, 2 H) MS (ESI+) for C23H32N6O Calc mass 408.26 Measured mass 409.2 (M+1) Example 17 - [3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2- yl]pyrrolidin-1-yl]-[4-(4-methyl-1-piperidyl)phenyl]methanone Step 1 - tert-butyl 4-(methylamino)-2-vinyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine- 6-carboxylate Done as INTERMEDIATE 2 with tert-butyl 2-chloro-4-(methylamino)-7,8-dihydro-5H- pyrido[4,3-d]pyrimidine-6-carboxylate (INTERMEDIATE 8) and purified by Silica gel chromatography eluded with iHexane:EtOAc 2:1 to give the alkene as an oil. Yield 162 mg. Step 2 - tert-butyl 4-(methylamino)-2-vinyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine- 6-carboxylate The product from step 1 was dissolved in DCM (20 mL) and TFA (5 eq) was added and the solution was chilled in ice with stirring. A solution of N-(methoxymethyl)-1-phenyl- N-(trimethylsilylmethyl)methanamine (0.21mL, 0.84mmol) in DCM (10 mL) was added during 30 minutes and left stirring on. The reaction was evaporated to give an oil that was purified by silica gel chromatography eluded with a gradient of DCM:methanol::NH3 aq 19(9):1:0.1. The product was isolated as an oil. Yield 28mg Step 3 tert-butyl 4-(methylamino)-2-pyrrolidin-3-yl-7,8-dihydro-5H-pyrido[4,3- d]pyrimidine-6-carboxylate 25 mg of the product from step 2 was hydrogenated over Pd / C (10%, wet (67% water content) 30 mg on in acetic acid (1mL) on as described for INTERMEDIATE 11. The product was used directly in step 4. Step 4 Was done with the product from step 3 as described in INTERMEDIATE 4 and Example 2. Yield 7mg.1H NMR (400 MHz, CHLOROFORM-d) į ppm 0.97 (d, J=6.38 Hz, 3 H) 1.20 - 1.38 (m, 2 H) 1.46 - 1.64 (m, 1 H) 1.72 (d, J=12.38 Hz, 2 H) 1.80 - 2.06 (m, 1 H) 2.20 - 2.42 (m, 2 H) 2.60 - 2.83 (m, 4 H) 2.96 - 3.06 (m, 3 H) 3.13 (br. s., 2 H) 3.36 - 3.58 (m, 1 H) 3.63 (d, J=9.63 Hz, 2 H) 3.69 - 3.77 (m, 3 H) 3.78 - 4.12 (m, 3 H) 4.36 (br. s., 1 H) 6.86 (d, J=8.13 Hz, 2 H) 7.50 (d, J=8.90 Hz, 2 H) MS (ESI+) for C25H34N6O Calc mass 434.28 Measured mass435.3 (M+1) Example 18 - [4-(4-methoxy-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2- yl)piperazin-1-yl]-[4-(4-methyl-1-piperidyl)phenyl]methanone; trifluoroacetic acid [4-(4-methoxy-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)piperazin-1-yl]-[4-(4- methyl-1-piperidyl)phenyl]methanone;trifluoroacetic acid (INTERMEDIATE 10) (32mg, 0.1mmol) was treated with Na2CO3 (sat, aq) solution and extracted with DCM, dried (NaSO4) and evaporated to give an oily product as the free amine as an oil. The oil was mixed with tert-butyl 2-chloro-4-methoxy-6,8-dihydro-5H-pyrido[3,4- d]pyrimidine-7-carboxylate (INTERMEDIATE 9) in DMC / methanol and evaporated in a 4 mL vial by N2 until almost a dry oil. The oil was treated at 130°C for 1h. The solid that had formed was scraped about in the vial and then heated at 150°C for 30 minutes. After cooling 2M HCl was added (0.5mL) and refluxed for 5 minutes The product was purified by reversed phase acidic preparative HPLC and lyophilized to give the title product as a beige solid Yield 6 mg. Triethylamine was added to a solution of tert-Butyl 4-(dimethylamino)-2-pyrrolidin-3- yl-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxylate (INTERMEDIATE 11) 26 mg, 0.072 mmol), 4-(4-methyl-1-piperidyl)benzoic acid (33 mg, 0.15 mmol) and HATU (82 mg, 0.22 mmol) in DMF (0.5mL) and stirred at rt on. 1M HCl (0.25mL) was added to the reaction and was heated to almost reflux for 5 min. NaHCO3(aq sat) and DCM was added. The water phase was extracted several times with DCM and finally with EtOAc. The pooled organic phases were washed with brine and dried (Na2SO4) and evaporated. The pure compound was achieved by silica gel chromatography eluded with DCM:MeOH:NH3 (aq) 19:1:0.1. Yield 9 mg.1H NMR (400 MHz, CHLOROFORM-d) į ppm 0.98 (d, J=6.50 Hz, 3 H) 1.23 - 1.40 (m, 2 H) 1.49 - 1.63 (m, 1 H) 1.73 (d, J=12.88 Hz, 2 H) 1.85 (br. s., 2 H) 2.60 (t, J=5.38 Hz, 2 H) 2.77 (td, J=12.38, 2.38 Hz, 2 H) 2.95 - 3.01 (m, 7 H) 3.57 - 3.80 (m, 9 H) 3.83 (s, 2 H) 6.90 (d, J=8.88 Hz, 2 H) 7.36 (d, J=8.75 Hz, 2 H) MS (ESI+) for C26H37N7O Calc mass 463.31 Measured mass 464.3 (M+1) Formulation example A pharmaceutical composition is obtained by mixing a therapeutically effective amount of a compound of formula I (such as a compound of Examples 1 to 19) with suitable excipients in suitable amounts. The resulting mixture is shaped to form a tablet. Optionally, a suitable coating is applied to the tablet.

[0002] Biological Examples The biological activity of example compounds as described herein was assessed using the following biological assays: Biological example 1: antiviral effect against lentivirus enveloped with Spike glycoprotein of SARS-CoV-2 Virus pseudotyping is a method that allows work with certain features of dangerous pathogenic viruses without the need of high biosafety level protocols. In the method, a viral glycoprotein, which drives the recognition of host cells, is expressed on the surface of a non-replicating lentivirus, thus mimicking the entry phase of infection. We have used this method to screen for and validate novel compounds that could inhibit infection with SARS-CoV-2 coronavirus. Spike-pseudotyped lentivirus was prepared in HEK 293T cells by transfecting the cells with 3 plasmids: packaging vector (psPAX2), transfer vector (pHR-cppt-CMV-GFP) and envelope vector (pCMV14-3xFlag-SARS-Cov-2-S). The plasmids were mixed in OPTIMEM at the molar ratio 1:1:2 and combined with Lipofectamine 2000 OPTIMEM solution. The transfection mixture was added to cells for 16 hours, after which medium was refreshed and virus-rich supernatant was collected after additional 48 hours. Supernatant was centrifuged to remove cell debris and stored at -80 ºC until used. In the infection assay, HEK 293T cells engineered to express human ACE2 receptor were seeded in a 384 well plate (BD Falcon or Corning) at 1’000 cells per well in 25 Njl. After 24 hours, a compound was added, and cells were incubated for 6 hours prior to infection with Spike-pseudovirus. Seventy-two hours after infection, cells were fixed with 4% formaldehyde solution for 15 minutes at room temperature, washed with PBS, and stained with Hoechst to fluorescently label DNA. Cells were imaged with a high throughput microscope (InCell 2200, Molecular Devices) using 10x objective and taking 4 fields per well. Images were analysed in batch using Cell Profiler (www.cellprofiler.org) and the infection rate was calculated as a ratio of GFP-positive cells to the total number of cells. Figure 1 shows the antiviral effect of Example 11. Biological example 2: antiviral effect against multiple variants of SARS-Cov-2 in cell lines The antiviral activity against different SARS-CoV-2 strains was tested in two different cell lines – Vero E6 (African green monkey kidney epithelial cells, ATCC nr CRL-1586) and A549-ACE2 (human lung adenocarcinoma cells ATCC nr CCL-185; engineered to over-express ACE2 receptor). Cells were seeded to 96 well plate and treated with compounds after 24 hours. Six hours after treatment start, growth medium was replaced with the virus solution (MOI = 0.1; strains details in Table 1), which was washed-off after 1 hour, and growth medium with compound was re-added. After 24 hours, cells were fixed with formaldehyde and washed with ethanol to inactivate the virus and sterilize the labware. Ethanol was washed-off with PBS and cells were immunostained with an antibody detecting the N-protein of SARS-CoV-2 (source) overnight at 4ºC; the antibody was diluted in 3% BSA / 0.1% Tween / PBS solution. Samples were washed with PBS and incubated with secondary staining solution composed of anti-rabbit antibody coupled with Alexa647 (ThermoFisher), Hoechst 33342 (ThermoFisher) and CellTracker Orange CMTMT (ThermoFisher); the concentrations were 1:1000, 2 NjM and 1 NjM, respectively. Staining was done for 1 hour at room temperature, followed by PBS wash. Cells were imaged with a high throughput microscope (InCell 2200, Molecular Devices) using 10x objective and taking 4 fields per well. Images were analysed in batch using Cell Profiler, and the infection rate was calculated as a ratio of virus signal-positive cells to the total number of cells. Similar assay as described above was used to test a series of analogues. To estimate their IC50 concentration, a broader dose range was tested. Cells were seeded together with the pre-plated compounds and SARS-CoV-2 Wuhan strain was added after 6 hours, without media change. Samples were processed 24 hours post infection in the same way as described above. Calculated IC50 values are listed in Table 2. Table 1: SARS-CoV-2 variants used in the Biological Example 2. Short name Strain id details Isolate SARS-CoV-2 / human / SWE / 01 / 2020; Genbank accession Wuhan MT093571 UK hCov-19 / Sweden / 21-53839 / 2021 Delta SARS-CoV-2 / hu / DK / SSI-H11 Omicron BA.1 hCov-19 / Sweden / 21-55629_SWE_i1 / 2021 Table 2: Compounds tested for the antiviral activity at dose 0.313-40 NjM. IC50 values were calculated in GraphPad Prism by sigmoidal 4PL curve fitting. Example nr IC50 (ʅM) 1 4.408 2 2.012 3 4.027 4 n.t. 5 n.t. 6 n.t. 7 n.t. 8 5.131 9 2.419 10 2.565 11 n.t. 12 4.293 13 5.184 14 n.t. 15 4.491 16 n.t. 17 4.356 18 n.t. 19 3.308 n.t. represents “not tested”. Biological example 3: antiviral effect against SARS-CoV-2 in liver spheroids. Antiviral activity was tested in liver spheroids, a pre-clinical model of SARS-CoV-2 infection. Primary human hepatocytes were seeded at a density of 1,500 cells per well in 96 well ultra low attachment plates and spheroids formed over the course of six days in PHH culture medium (Williams E medium supplemented with 2 mM L-glutamine, 100ௗunits / ml penicillin, 100ௗNjg / ml streptomycin, 10ௗNjg / ml insulin, 5.5ௗNjg / ml transferrin, 6.7ௗng / ml sodium selenite, 100ௗnM dexamethasone) supplemented with 10% fetal bovine serum. After spheroids were formed, the medium was changed to serum-free PHH culture medium. Spheroids were then exposed overnight to compounds and infected with SARS-CoV-2 Alpha strain (hCoV-19 / sweden720-53846 / 2020) at a multiplicity of infection of 1 for 24 hours. After 24 hours, four spheroids per condition were pooled and washed 3 times with PBS before lysis. RNA was extracted and purified using the Quick-RNA Microprep Kit (Zymo Research Irvine, CA, USA) and relative levels of viral RNA were determined by qRT-PCR. The result obtained for Example 11 is shown in Figure 3. Biological example 4: antiviral effect against Monkeypox and Tick-borne Encephalitis viruses To test if the compound has a broader antiviral activity, they were tested for their potential to inhibit infection with Monkeypox and Tick-borne encephalitis viruses, both of which are enveloped viruses. A549-ACE2 cells were seeded into 96 well plates together with pre-plates compounds. After 6 hours, cells were infected with viral stocks (Monkeypox MOI = 0.05, TBEV MOI = 0.5; strains details in Table 3). Infection rate was assayed 24 hours post infection by microscopy after staining the cells with antibodies against viruses: anti-Vaccinia (abcam 35219) for Monkeypox and anti-TBEV (BioTechne MAB10106-100). Data obtained for Example 11 is presented in the Figure 4. The compound showed inhibitory activity against the tested viruses. Table 3: Monkeypox and TBEC variants used in the Biological Example 4 Short name Strain id details Isolate SARS-CoV-2 / human / SWE / 01 / 2020; Genbank accession Monkeypox MT093571 TBEV Sofjin isolate; passage history unknown

Claims

Claims 1. A compound of formula (I):or a pharmaceutically acceptable salt thereof, for use in preventing or treating an infection with an enveloped virus, wherein: L represents -C(O)-, -S(O)2- or -N(R7)C(O)-; n represents 1 to 5; m represents 1 or 2; each R1independently represents (a) C1-12alkyl, C2-12alkenyl or C2-12alkynyl each optionally substituted by one or more groups independently selected from G1a, (b) -ORa1, (c) -SO2Rb1, (d) halo, (e) aryl optionally substituted by one or more groups independently selected from G1b, (f) heteroaryl optionally substituted by one or more groups independently selected from G1c, or (g) heterocyclyl optionally substituted by one or more groups independently selected from G1d; and any two adjacent R1groups together with the carbons to which they are attached may alternatively form an aryl ring, optionally substituted by one or more groups independently selected from G1b; Ra1represents C2-12 alkyl optionally substituted by one or more groups independently selected from G2a;Rb1represents C1-12 alkyl optionally substituted by one or more groups independently selected from G3a; each G1a, G2a, G3a, G4a, G5a, G6a, and G7aindependently represents halo, -CN, - N(Rb2)Rc2, -ORd2, -SRe2or =O; each G1band G1cindependently represents halo, Ra2, -CN, -N(Rb2)Rc2, -ORd2, or -SRe2; each G1dindependently represents halo, Ra2, -CN, -N(Rb2)Rc2, -ORd2, -SRe2, or =O; each Ra2represents C1-6 alkyl optionally substituted by one or more groups independently selected from G4a; each Rb2, Rc2, Rd2, and Re2independently represents H or C1-6 alkyl, C2-6 alkenyl or C2- 6 alkynyl each optionally substituted by one or more fluoro; or Rb2and Rc2are linked together to form, along with the nitrogen atom to which they are attached, a 3- to 6-membered ring, which ring optionally contains one further heteroatom and which ring optionally is substituted by one or more groups independently selected from fluoro, C1-3 alkyl, C2-3 alkenyl or C2-3 alkynyl each optionally substituted by one or more fluoro; R2represents -NR3R4or -OR5; R3represents H or C1-6 alkyl optionally substituted by one or more groups independently selected from G5a; R4represents C1-6 alkyl optionally substituted by one or more groups independently selected from G6a; R5represents C1-6alkyl; one of X and Z represents NR6, and the other represents CH2; Y represents CH or N; R6represents H, C1-6 alkyl optionally substituted by one or more groups independently selected from G7a;R7represents H or C1-6 alkyl; wherein each alkyl, alkenyl, and alkynyl group may be linear, branched, or where there is a sufficient number of carbons, may be cyclic or part cyclic.

2. A compound for use as claimed in Claim 1, wherein the enveloped virus is a coronavirus.

3. A compound for use as claimed in Claim 2, wherein the coronavirus is an alphacoronavirus or a betacoronavirus.

4. A compound for use as claimed in Claim 3, wherein the alphacoronavirus is Human coronavirus 229E (HCoV-229E) or Human coronavirus NL63 (HCoV-NL63).

5. A compound for use as claimed in Claim 3, wherein the betacoronavirus is selected from the group consisting of severe acute respiratory syndrome-related coronavirus, Middle East respiratory syndrome (MERS), SARS-Cov-2, Human coronavirus OC43, Human coronavirus HKU1.

6. A compound for use as claimed in Claim 5, wherein the severe acute respiratory syndrome-related coronavirus is SARS-Cov-1 or SARS-Cov-2.

7. A compound for use as claimed in Claim 1, wherein the enveloped virus is a virus of Orthopoxvirus genus, such as a virus of Poxviridae family, such as a virus of Chordopoxviridae subfamily.

8. A compound for use as claimed in Claim 7, wherein the enveloped virus is monkeypox, cowpox, smallpox, camelpox, or horsepox, such as monkeypox.

9. A compound for use as claimed in Claim 1, wherein the enveloped virus is a virus of Flavivirus genus, such as a virus of Flaviviridae family.

10. A compound for use as claimed in Claim 9, wherein the enveloped virus is Tick- borne Encephalitis Virus (TBEV), Zika, Dengue, West Nile, or Yellow fever, such as TBEV.

11. A compound for use as claimed in any one of Claims 1 to 10, wherein n represents 1 to 3, such as n represents 1.

12. A compound for use as claimed in any one of Claims 1 to 11, wherein R1independently represents (a) C1-12 alkyl (such as C2-12 alkyl), C2-12 alkenyl or C2-12 alkynyl each optionally substituted by one or more groups independently selected from G1a, (b) -ORa1, (c) -SO2Rb1, (d) halo, (e) aryl optionally substituted by one or more groups independently selected from G1b, (f) or heterocyclyl optionally substituted by one or more groups independently selected from G1d.

13. A compound for use as claimed in any one of Claims 1 to 12, wherein at least one of the R1groups represents C2-8 alkyl, such as C2-6 alkyl.

14. A compound for use as claimed in any one of Claims 1 to 12, wherein at least one of the R1groups represents -ORa1, wherein Ra1represents C2-8 alkyl, such as C2-6 alkyl.

15. A compound for use as claimed in any one of Claims 1 to 12, wherein at least one of the R1groups represents phenyl, optionally substituted by one or more groups independently selected from G1b.

16. A compound for use as claimed in any one of Claims 1 to 12, wherein at least one of the R1groups represents heterocyclyl, wherein the heterocyclyl contains only one heteroatom, and the heteroatom is the point of attachment to the remainder of the molecule.

17. A compound for use as claimed in any one of Claims 1 to 16, wherein one of the R1groups is attached at the 4-position of the phenyl ring.

18. A compound for use as claimed in any one of Claims 1 to 17, wherein R2represents -NR3R4.

19. A compound for use as claimed in any one of Claims 1 to 18, wherein the compound is selected from the list consisting of:[3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl]pyrrolidin-1-yl]- [4-(4-methyl-1-piperidyl)phenyl]methanone; [3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl]pyrrolidin-1-yl]- (4-pentylphenyl)methanone; (4-butylphenyl)-[3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2- yl]pyrrolidin-1-yl]methanone; [3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl]pyrrolidin-1-yl]- (4-propylphenyl)methanone; (4-ethylphenyl)-[3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2- yl]pyrrolidin-1-yl]methanone; [3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl]pyrrolidin-1-yl]- (2-naphthyl)methanone; (4-butoxyphenyl)-[3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2- yl]pyrrolidin-1-yl]methanone; [3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl]pyrrolidin-1-yl]- (4-phenylphenyl)methanone; (4-cyclohexylphenyl)-[3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin- 2-yl]pyrrolidin-1-yl]methanone; [4-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl]piperazin-1-yl]- [4-(4-methyl-1-piperidyl)phenyl]methanone; [3-[7-methyl-4-(methylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-2- yl]pyrrolidin-1-yl]-[4-(4-methyl-1-piperidyl)phenyl]methanone; [3-[4-(dimethylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl]pyrrolidin-1- yl]-[4-(4-methyl-1-piperidyl)phenyl]methanone; N-methyl-2-[1-(4-phenylphenyl)sulfonylpyrrolidin-3-yl]-5,6,7,8- tetrahydropyrido[3,4-d]pyrimidin-4-amine; 2-[1-(4-butylphenyl)sulfonylpyrrolidin-3-yl]-N-methyl-5,6,7,8-tetrahydropyrido[3,4- d]pyrimidin-4-amine; 3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl]-N-(4- phenylphenyl)pyrrolidine-1-carboxamide; N-(4-butylphenyl)-3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2- yl]pyrrolidine-1-carboxamide;[3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-yl]pyrrolidin-1-yl]- [4-(4-methyl-1-piperidyl)phenyl]methanone; [4-(4-methoxy-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)piperazin-1-yl]-[4-(4- methyl-1-piperidyl)phenyl]methanone; and [4-[4-(dimethylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl]piperazin-1- yl]-[4-(4-methyl-1-piperidyl)phenyl]methanone; and pharmaceutically acceptable salts thereof.

20. A compound of formula (I) according to any one of claims 1 to 19, or a pharmaceutically acceptable salt thereof, wherein the following compounds are excluded: (4-(ethoxymethyl)phenyl)(3-(7-methyl-4-(methylamino)-5,6,7,8- tetrahydropyrido[3,4-d]pyrimidin-2-yl)pyrrolidine-1-yl)methanone; [1,1'-biphenyl]-2-yl(3-(7-methyl-4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4- d]pyrimidin-2-yl)pyrrolidin-1-yl)methanone; [3-[7-methyl-4-(methylamino)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-2- yl]pyrrolidin-1-yl]-[4-(4-methyl-1-piperidyl)phenyl]methanone; 1-(4-(3-(7-methyl-4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2- yl)pyrrolidine-1-carbonyl)phenyl)pyrrolidin-2-one; [1,1'-biphenyl]-2-yl(3-(6-methyl-4-(methylamino)-5,6,7,8-tetrahydropyrido[4,3- d]pyrimidin-2-yl)pyrrolidin-1-yl)methanone; and 1-(3-(3-(6-methyl-4-(methylamino)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2- yl)pyrrolidine-1-carbonyl)phenyl)pyrrolidin-2-one.

21. A compound as claimed in Claim 20, wherein the compound is selected from the list consisting of: [3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl]pyrrolidin-1-yl]- [4-(4-methyl-1-piperidyl)phenyl]methanone; [3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl]pyrrolidin-1-yl]- (4-pentylphenyl)methanone;(4-butylphenyl)-[3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2- yl]pyrrolidin-1-yl]methanone; [3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl]pyrrolidin-1-yl]- (4-propylphenyl)methanone; (4-ethylphenyl)-[3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2- yl]pyrrolidin-1-yl]methanone; [3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl]pyrrolidin-1-yl]- (2-naphthyl)methanone; (4-butoxyphenyl)-[3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2- yl]pyrrolidin-1-yl]methanone; [3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl]pyrrolidin-1-yl]- (4-phenylphenyl)methanone; (4-cyclohexylphenyl)-[3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin- 2-yl]pyrrolidin-1-yl]methanone; [4-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl]piperazin-1-yl]- [4-(4-methyl-1-piperidyl)phenyl]methanone; [3-[4-(dimethylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl]pyrrolidin-1- yl]-[4-(4-methyl-1-piperidyl)phenyl]methanone; N-methyl-2-[1-(4-phenylphenyl)sulfonylpyrrolidin-3-yl]-5,6,7,8- tetrahydropyrido[3,4-d]pyrimidin-4-amine; 2-[1-(4-butylphenyl)sulfonylpyrrolidin-3-yl]-N-methyl-5,6,7,8-tetrahydropyrido[3,4- d]pyrimidin-4-amine; 3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl]-N-(4- phenylphenyl)pyrrolidine-1-carboxamide; N-(4-butylphenyl)-3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2- yl]pyrrolidine-1-carboxamide; [3-[4-(methylamino)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-yl]pyrrolidin-1-yl]- [4-(4-methyl-1-piperidyl)phenyl]methanone; [4-(4-methoxy-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)piperazin-1-yl]-[4-(4- methyl-1-piperidyl)phenyl]methanone; and [4-[4-(dimethylamino)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl]piperazin-1- yl]-[4-(4-methyl-1-piperidyl)phenyl]methanone;and pharmaceutically acceptable salts thereof.

22. A pharmaceutical composition comprising a compound as defined in any of the preceding claims, and optionally one or more pharmaceutically acceptable adjuvants, diluent and / or carrier.

23. The use of a compound as defined in any one of Claims 1 to 21, for the manufacture of a medicament for preventing or treating an infection with an enveloped virus.

24. A method of preventing or treating an infection with an enveloped virus, comprising administering to a patient in need thereof a therapeutically effective amount of a compound as defined in any one of Claims 1 to 21.

25. The use or method as claimed in Claim 23 or 24, wherein the enveloped virus is a coronavirus, a virus of the Orthopoxvirus genus, or a virus of the Flavivirus genus.

26. A process for the preparation of a compound as claimed in Claim 20 or 21, or a pharmaceutically acceptable salt thereof, comprising the step of: (i) where L represents -C(O)- or -S(O)2-, reaction of a compound of formula IIwherein X, Y, Z, R2and m are as defined in Claim 20 or 21, with a compound of formula IIIwherein R1and n are as defined herein, and wherein RX1represents a suitable leaving group, under conditions known to those skilled in the art; (ii) where L represents -NHC(O)-, reaction of a compound of formula II, wherein X, Y, Z, R2and m are as defined herein, with a compound of formula IVwherein R1and n are as defined in Claim 20 or 21, under conditions known to those skilled in the art; (iii) where Y represents NH, reaction of a compound of formula V,wherein R1, n, m, and L are as defined in Claim 20 or 21, with a compound of formula VIwherein R2, X and Z are as defined in Claim 20 or 21, wherein when representing nitrogen, X or Z are further attached to a suitable protecting group, and RX2represents a suitable halide, under conditions known to those skilled in the art.

Citation Information

Patent Citations

  • Pyridopyrimidine HIV (Human Immunodeficiency Virus)-1 reverse transcriptase inhibitor as well as preparation method and application thereof

    CN108409734A

  • Novel tetrahydropyridopyrimidines for the treatment and prophylaxis of hepatitis b virus infection

    WO2018083081A1